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Abstract 
Primary Sclerosing Cholangitis (PSC) is a progressive liver disease of unknown 
etiology. This disease can lead to many potential lethal clinical situations including liver 
cirrhosis. Ursodeoxycholic acid (UDCA) has been shown to be effective in other 
cholestatic liver diseases, most notably primary biliary cirrhosis. A number of randomized 
controlled trials (RCTs) using UDCA for the treatment ofPSC have been carried out with 
varying results. The main objective of this study was to determine if the literature 
provides evidence that UDCA is effective at prolonging survival in patients with PSC. 
Meta-analysis was used to evaluate the effect ofUDCA on disease progression in 
patients with PSC. Only RCTs that compared UDCA to placebo in patients with PSC 
were included. Six fully published RCTs that met the inclusion criteria for this meta-
analysis were identified in the literature. The outcome measurements used for this study 
included overall mortality and the requirement for liver transplant. Surrogate markers for 
the primary outcome of overall mortality were also analyzed and included worsening of 
liver histology, AST (U/L), ALP (U/L), albumin (giL) and bilirubin (umol/L) levels. 
Subgroup analysis was also performed comparing high dose(> 15mglkg/day) to 
low/standard dosing ( 1 0-15mg/kg/day) of UDCA in patients with PSC for the primary 
outcome of overall mortality. 
Pooling of the six fully published RCTs, identified a non-significant difference 
between treatment groups for the outcome of all cause mortality with an odds ratio of 
0.859 and (95% confidence interval (CI), 0.365- 2.022, p=0.728). A subgroup analysis of 
overall mortality stratified according to UDCA dosing did not identify any statistically 
significant difference in survival regardless of the dose ofUDCA administered. A non-
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significant difference between treatment groups for the pooled results of the outcome liver 
transplant required yielded an odds ratio 1.243 with (95%CI, 0.667-2.317, p=0.494). A 
non-significant difference between treatment groups was observed for the surrogate 
outcome worsening of liver histology with an odds ratio of 0.903 and (95%CI, 0.316-
2.582, p=0.849). The pooled standardized mean difference (SMD) was calculated for the 
surrogate outcomes ofliver biochemistry (AST (U/L), ALP (U/L)) and liver function 
(bilirubin (umol/L), albumin (giL)). All surrogate outcomes suggested a benefit favoring 
UDCA, however, only AST (U/L), ALP (U/L) and bilirubin (umol/L) were statistically 
significant with a p-value <0.05. 
These results indicate that although UDCA improved surrogate outcomes such as 
liver biochemistry and liver function, the results did not translate into a reduction in 
endpoints such as mortality or a need for liver transplant. This meta-analysis suggests that 
high dose UDCA (> 15mg/kg/day) does not offer any treatment benefit over low/standard 
dosing (1 0-15mg/kg/day) for the outcome overall mortality in patients with PSC. Further 
research is needed to identify an effective medication to halt the progression of this 
disease. Future research may detem1ine if starting therapy with UDCA at an earlier stage 
of disease translates into a survival advantage for patients with PSC. 
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Chapter 1 
Introduction 
This chapter will provide an overview of the disease primary sclerosing 
cholangitis (PSC). The seriousness of this illness and the need for effective treatment 
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will be discussed. Ursodeoxycholic acid (UDCA) will be introduced as an effective drug 
used in other cholestatic liver diseases. The usefulness ofUDCA for patients in PSC will 
be explored and the results will lead to the development of a meta-analysis to determine if 
UDCA can prolong survival in patients with PSC. This chapter will also include the 
study objectives and research questions that will be investigated in this meta-analysis. 
1.1 Primary Sclerosing Cholangitis 
1.1.1 Definition and Overview. 
PSC is a chronic cholestatic liver disease that affects both intra and extrahepatic 
bile ducts. Chronic inflammation and fibrosis leads to progressive destruction of the bile 
ducts (Silveira & Lindor, Clinical Features and Management of Primary Sclerosing 
Cholangitis, 2008). Bile is produced in the liver, stored in the gallbladder and secreted 
into the small bowel after ingesting a meal to aid in digestion. This process can only 
occur if there are adequate bile ducts present to transport bile from the liver to the small 
bowel. In PSC, the primary site of damage is the biliary epithelium which does not have 
the ability to regenerate like hepatocytes when injured (Mitchell & Chapman, 1997). 
This will lead to failure of biliary excretion if continued injury from inflammation and 
fibrosis occurs (Mitchell & Chapman, 1997). Once this happens, there is damage to the 
hepatocytes ultimately leading to cirrhosis and hepatic dysfunction. Cirrhosis is 
2 
characterized by fibrosis of the liver parenchyma. This in turn can lead to such 
complications as portal hypertension and hepatocellular carcinoma. Portal hypertension 
may manifest as ascites (an accumulation of fluid in the peritoneum), gastrointestinal (GI) 
bleeding from varices, hepatic encephalopathy and renal or pulmonary impairment. PSC 
has its own potential complications in addition to cirrhosis. Progressive destruction of 
the bile ducts can lead to sepsis from infection within the biliary tree (cholangitis). 
Jaundice can occur from a dominant stricture in the extrahepatic biliary system. PSC has 
also been associated with an increased incidence of certain malignancies. 
Cholangiocarcinoma, gallbladder cancer, hepatocellular carcinoma and colon cancer all 
occur in higher frequencies among patients with PSC (Silveira & Lindor, Clinical 
Features and Management ofPrimary Sclerosing Cholangitis, 2008). 
1.1.2 Epidemiology. 
A Canadian population based study has shown that the incidence ofPSC is 0.92 
cases per l 00,000 person years (Kaplan, Laupland, Butzner, Urbanski, & Lee, 2007). 
The reported incidence is similar to other studies carried out in the United States and 
Europe. A population based estimate of the prevalence of PSC conducted in the United 
States revealed a rate of 13.6 per 100,000 people (Bambha, et al., 2003). Two thirds of 
patients with PSC are male with a mean age at diagnosis of forty years (Silveira & 
Lindor, Primary Sclerosing Cholangitis, 2008). PSC is highly associated with 
inflammatory bowel disease (lBO), particularly ulcerative colitis (UC). Approximately 
75% of patients with PSC are found to have UC (Wiesner & LaRusso, 1980). However, 
only about 2-6% of patients with UC have PSC (Chapman, 2003). It is therefore not 
surprising that even with a high prevalence ofUC in the population, PSC remains a rare 
diagnosis. 
1.1.3 Etiology and Pathogenesis. 
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There are currently several theories to explain the etiology and pathogenesis of 
PSC. Several investigators have hypothesized that a dysregulated immune system may 
lead to PSC. Reports of tissue lymphocyte populations, abnormal cytokines and the 
aberrant expression of human leukocyte antigen (HLA) class II molecules on the bile duct 
epithelium have provided some evidence that PSC is an immune mediated disease 
(Cullen & Chapman, 2005). This research may explain a potentially exaggerated cell 
mediated immune response targeted at the bile duct epithelium leading to the features 
seen in PSC. 
Other researchers have sought to prove a genetic link to the pathogenesis of PSC. 
There is an increased incidence ofPSC in patients who have first-degree relatives with 
the disease. Hazard ratios of 11.5, 11.1 and 2.3 were reported for the risk of developing 
PSC in an offspring, sibling or parent, respectively in a PSC patient cohort compared to a 
cohort of patients without PSC (Bergquist, et al. , 2008). Patients with PSC have been 
found to have an increased prevalence of HLA-B8, -DR3, and -DRw52a (Van Milligen 
de Wit, VanDeventer, & Tytgat, 1995). DR2 appears to be associated with a younger 
onset of the disease whereas DR4 seems to identify more rapid disease progression 
(Portincasa, et al., 2005). 
The strong association between PSC and UC has led investigators to consider the 
possibility of a bacterial etiology for the pathogenesis ofPSC. The theory is that bacteria 
---- - --------------------
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can trans-locate across an inflamed colonic wall and migrate to the portal circulation 
where a chronic inflammatory response can occur in the biliary tract leading to fibrosis 
(Lee & Kaplan, 1995). This theory has not been validated in the literature and recent 
results have not shown any evidence to support the role of bacteria in the pathogenesis of 
PSC (Cullen & Chapman, 2005). 
Another theory linking IBD and PSC suggests that mucosal lymphocytes 
produced in the colonic wall during an active flare of IBD persist as memory cells in the 
enterohepatic circulation. These gut derived lymphocytes can then become activated to 
produce biliary inflammation. This theory has been supported by literature showing that 
some lymphocyte homing receptors are shared by both the colon and liver (Grant, Lalor, 
Hubscher, Briskin, & Adams, 200 I). 
1.1.4 Diagnosis. 
The diagnosis of PSC often occurs in asymptomatic patients presenting with 
raised cholestatic liver enzymes on laboratory evaluations. Approximately 15-55% of 
patients with PSC are asymptomatic at the time of diagnosis (Silveira & Lindor, Primary 
Sclerosing Cholangitis, 2008). An elevation of alkaline phosphatase (ALP) is the 
biochemical hallmark of PSC (Wiesner & LaRusso, 1980). Increases in the serum 
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are usually only 
mild to moderate. Once the diagnosis is suspected, usually in the patient with UC who 
has a rise in ALP, other serological tests can be ordered with differing sensitivities and 
specificities for the diagnosis of PSC. Antinuclear antibody (ANA) can be found in low 
titers in 20-60% of patients (Silveira & Lindor, Clinical Features and Management of 
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Primary Sclerosing Cholangitis, 2008). Anti-mitochondrial antibodies, seen frequently in 
patients with another cholestatic liver disease - primary biliary cirrhosis (PBC), are rarely 
seen in patients with PSC (Wiesner & LaRusso, 1980). Perinuclear antineutrophil 
cytoplasmic autoantibody (p-ANCA) can be found in patients with PSC with a sensitivity 
of 49% and a specificity of 89% making it a useful serologic test to help rule in the 
diagnosis of PSC (Bansi, Chapman, & Fleming, 1996). 
PSC is usually confirmed radiographically. Modalities such as endoscopic 
retrograde cholangiopancreatography (ERCP) and magnetic resonance 
cholangiopancreatography (MRCP) are very sensitive and specific at diagnosing PSC. 
These imaging modalities will identify the classic features of PSC including diffuse 
multifocal strictures usually involving both the intra and extra hepatic bile ducts. The 
strictures seen are typically short and annular alternating with normal or minimally 
dilated segments to produce a characteristic "beaded" appearance (MacCarty, LaRusso, 
Wiesner, & Ludwig, 1983). 
1.1.5 Pathology. 
The histological changes in PSC can be very patchy. Anatomically, the bile ducts 
are distributed throughout the liver and can have varying amounts of inflammation and 
fibrosis. It is therefore understandable that a liver biopsy, which may only sample a few 
bile ducts, can demonstrate anything from normal bile ducts to frank biliary cirrhosis 
(Cullen & Chapman, 2005). This low sensitivity for liver biopsy makes it less favorable 
to be the sole method of diagnosing PSC. Liver histology is however useful for 
identifying the grade of PSC. Since 1981 a comprehensive grading system has been 
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created in order to determine the severity ofPSC in liver samples. The histologic 
findings initially start in the portal triad (bile duct, portal vein, hepatic artery) and 
eventually spread to the hepatic parenchyma. There are four stages in the grading system 
for PSC. Stage 1 consists of enlargement, edema, and scarring of the portal triads, and 
mononuclear cell infiltration with some piecemeal necrosis and damage to isolated bile 
ducts. Stage li consists of expansion of portal triads with fibrosis extending into the 
surrounding parenchyma. Stage III is characterized by bridging fibrosis and stage IV 
represents cirrhosis (Ludwig, Barham, LaRusso, Elveback, Wiesner, & McCall, 1981 ). 
1.1.6 Natural History. 
PSC has a variable course from one patient to another; however, overall this 
chronic liver disease is progressive with a mean survival of 12 years (Farrant, et al., 
1991 ). Disease progression and prognosis can be determined using a scoring system 
called the Mayo risk score. This is a scoring system that uses several surrogate markers 
in order to predict the natural history in an individual. A surrogate marker is defined as a 
laboratory investigation or any other intermediate substitute that is used to evaluate a 
treatment response on a clinically meaningful outcome measure. (Gluud, Brok, Gong, & 
Koretz, 2007). The Mayo risk score is calculated using serum bilirubin, AST, albumin, 
the patients' age and whether they have previously had variceal bleeding (Kim, Themeau, 
& Wiesner, 2000). 
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1.1.7 Complications. 
Several complications can occur as PSC progresses in severity. Portal 
hypertension (ascites, GI bleeding, hepatic encephalopathy), liver failure, cholestasis, 
cholelithiasis and choledocholithiasis have all been reported (Portincasa, et al. , 2005). GI 
bleeding can also occur in patients with UC from peristomal varices after 
proctocolectomy and ileal stoma formation (Chapman, 2003). Cholestasis can lead to fat 
malabsorption which in turn can result in deficiency of the fat-soluble vitamins A,D,E 
and K. It has been reported that vitamin A deficiency occurs in up to 50% of patients 
with PSC (Portincasa, et al. , 2005). Osteoporosis is a known complication that may be 
related to the osteoblast inhibitors found in the serum of patients with cholestasis (Janes, 
Dickson, Okazaki, Bonde, McDonagh, & Riggs, 1995). Dominant extrahepatic strictures 
may occur in 15-20% of patients with PSC, leading to further complications such as 
jaundice, fever, pruritus and anorexia (Portincasa, et al. , 2005). There is an increased risk 
of malignancy in patients with PSC. The most widely reported malignancy is 
cholangiocarcinoma that caries a lifetime risk of I 0-15% (Lee & Kaplan, 1995). It may 
be difficult to distinguish between a dominant extrahepatic stricture and 
cholangiocarcinoma. The diagnosis of cholangiocarcinoma should be considered in 
patients who have rapid clinical deterioration including jaundice, weight loss and 
abdominal pain (Rosen, Nagorney, Wiesner, Coffey, & LaRusso, 1991). The young age 
of disease onset and inevitable progression of PSC along with the severe potential 
complications suggest a need for effective medical or surgical treatment that can halt the 
natural history of PSC. 
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1.1.8 Management. 
The only effective treatment to date for PSC is liver transplantation. Five-year 
survival has been reported as high as 89% following liver transplantation (Farges, 
Malassagne, Sebagh, & Bismuth, 1995). The majority of liver transplants occur after 
there has been liver decompensation manifested by ascites, GI bleeding or hepatic 
encephalopathy. There has been debate about the optimal timing for liver transplant in 
patients with PSC as individuals with this disease can appear well and deteriorate quickly 
from complications such as cholangiocarcinoma. Patients with PSC are also considered 
for liver transplantation if they have intractable pruritus, fatigue or recurrent cholangitis 
(Silveira & Lindor, Primary Sclerosing Cholangitis, 2008). Unfortunately, liver 
transplantation does not provide a cure for PSC. There are reports of recurrent PSC in the 
liver graft in 2-40% of transplanted patients (Gautam, Cheruvattath, & Balan, 2006). 
Another potential consideration is the increased risk of colon cancer in patients with UC 
post transplant (Vera, et al. , 2003). Liver transplantation is a surgical procedure with 
related morbidity and mortality. This procedure does not offer a cure of PSC and there is 
the potential increased risk of malignancy following transplantation. It is understandable 
that many physicians and patients are interested in delaying transplant as long as possible. 
The only way to successfully achieve this goal is to find a medication that can halt or 
reverse fibrosis and inflammation of the biliary tract as well as decrease the incidence of 
cholangiocarcinoma. 
Throughout the past three decades, there has been a lot of interest in finding an 
effective medical treatment for patients with PSC. Treatments have focused on managing 
the symptoms and complications of the disease. There is also ongoing research into 
treatments that can halt or reverse the course of this disease. 
9 
There are complications related to PSC that are common to all end stage liver 
disease. These include manifestations of portal hypertension such as ascites, 
encephalopathy, GI bleeding from varices as well as renal and pulmonary disease. These 
conditions are managed in the same way irrespective of the etiology ofliver disease. A 
complication that is more common in patients with PSC includes bleeding from stomal 
varices post colectomy in UC patients (Wiesner R. , LaRusso, Dozois, & Beaver, 1986). 
Ideally, patients with PSC who require a colectomy for active UC should have an ileal-
pouch-anal anastamosis procedure in order to avoid an ileal stoma (Mitchell & Chapman, 
1998). In order to facilitate the construction of this pouch, the surgeon needs to leave 
some rectum behind for the anastamosis. There is an increased risk of colonic/rectal 
malignancy in patients with PSC and UC and therefore annual surveillance of the rectum 
and pouch with random biopsies using a flexible sigmoidoscope is recommended 
(Chapman, 2003). 
Dominant biliary strictures are another complication that can occur in patients 
with PSC. These extrahepatic strictures may cause a reduction in the flow of bile leading 
to a more rapid clinical deterioration and biliary cirrhosis. In one study, dominant 
strictures occurred in 40% of patients with PSC over a five-year period (Stielh, Rudolph, 
Kloters-Plachky, Sauer, & Walker, 2002). At the present time, dominant strictures can be 
treated surgically or endoscopically. There are reports of good outcomes with biliary-
enteric drainage ofbile through surgical bypass of the strictured segment (Myburgh, 
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1994). However, surgical reconstruction and bypass are not done routinely for strictures 
as there are reports of scarring in the bile duct which may complicate future liver 
transplants (Chapman, 2003 ). There is also evidence to suggest that instead of a surgical 
reconstruction or bypass, liver transplantation may be a better option for the patient with 
five-year survivals of 89% post liver transplant (Farges, Malassagne, Sebagh, & Bismuth, 
1995). Endoscopic treatments involve the use of ERCP in order to access the common 
bile duct (CBD) and to traverse the stricture with a guide wire in order to perform balloon 
dilatation and stenting of the stricture. This procedure facilitates the uninterrupted flow of 
bile. There are however reports of increased rates of cholangitis in patients with PSC 
undergoing ERCP (Mitchell & Chapman, 1998). It is likely that the introduction of 
bacteria into a biliary system containing intrahepatic strictures leads to this increased 
frequency of cholangitis. 
Dominant strictures can often be difficult to differentiate from 
cholangiocarcinoma. ERCP permits brush cytology of the stricture in order to check for 
malignant cells; however, the sensitivity of a correct diagnosis is only 46% (Siqueira, et 
al., 2002). A combination oftumor markers using CA 19-9 and carcinoembryonic 
antigen (CEA) may be useful for identifying PSC patients with malignant strictures. In 
one study the combination of an abnormal CEA or CA 19-9 demonstrated a sensitivity of 
100%, [95% confidence interval (CI) 65-1 00] and a specificity of 78.4%, [95% CI 63.1-
89.7] (Siqueira, et al., 2002). 
Several medications have been used to try and halt the progression of PSC. The 
rationale for these choices is largely based on the pathophysiology ofPSC. Medications 
that have been tried include those used in other cholestatic liver diseases, most notably 
primary biliary cirrhosis (PBC). 
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Increased copper levels have been detected in all patients with prolonged 
cholestasis. This observation led to the use of D-penicillamine in a randomized controlled 
trial (RCT) for patients with PSC. D-penicillamine is widely known as a copper chelator 
used to successfully treat Wilsons disease, a condition characterized by copper overload. 
In patients with PSC, no improvement on disease progression or overall survival was 
found in the treatment group. There were significant side effects including pancytopenia 
and proteinuria that led to drug discontinuation in 21% of patients (LaRusso, Wiesner, & 
Ludwig, 1988). 
Colchicine is an antifibrogenic agent used in other cholestatic liver diseases with 
varying success. It has not been found to be successful to date in patients with PSC. In 
one study, 44 patients were randomized to lmg/day of colchicine and 40 patients were 
randomized to placebo. At three years it was determined that there was no difference in 
liver biochemistry, liver histology or overall survival between the two groups (Olsson, et 
al. , 1995). 
Corticosteroids have been investigated for the treatment of patients with PSC. It 
was hypothesized that PSC is partly immune mediated and therefore corticosteroids used 
in other immune mediated conditions might provide some benefit to patients with PSC. 
The majority of patients with PSC also have UC. Steroids are the mainstay of treatment 
in active UC; however, when used in patients with PSC there has been very little 
improvement in the liver disease. There are also potentially severe long-term side effects 
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associated with corticosteroids that have discouraged large RCTs (Mitchell & Chapman, 
1998). The use of corticosteroids is not currently recommended for the treatment of 
patients with PSC. 
Several immunosuppressants have been used in the treatment of PSC. The most 
widely studied has been methotrexate. After encouraging findings in an open label study, 
an RCT compared oral pulse methotrexate at a dose of 15mg per week with a placebo 
group. The results showed that the only significant change was a fall in the liver enzyme 
ALP by 31%. Histology and cholangiographic parameters were unchanged (Knox & 
Kaplan, 1994). A pilot study using methotrexate and UDCA was performed by Lindor, et 
al; with similar negative results to the above RCT (Lindor, Jorgensen, & Anderson, 
1996). Given the potential serious side effects of methotrexate including lung disease, 
hepatotoxicity and pancytopenia, there likely will not be a larger controlled trial using 
methotrexate in patients with PSC. 
Other immunosuppressants reported in the literature to treat PSC have not been 
well studied and include azathioprine, cyclosporine and tacrolimus (Chapman, 2003). At 
the present time none of these medications are recommended routinely for the treatment 
of patients with PSC. 
1.2 Ursodeoxycholic Acid 
1.2.1 Structure and Overview. 
UDCA is a medication that has been evaluated more than any other for the 
treatment ofPSC. It is particularly attractive as a potential treatment for patients with 
PSC because of its known hepatoprotective properties. UDCA is a hydrophilic 
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dihydroxy (3a,7~-dihydroxy-5~-cholan-24oic acid) bile acid that accounts for 3% of the 
bile acid pool in adults (Paumgartner & Beuers, 2002). UDCA is not synthesized in the 
liver and is thought to be formed in the colon by bacterial 7~ epimerization of the 
primary bile acid chenodeoxycholic acid. In tum, UDCA is then passively absorbed by 
the colonic mucosa and enters the portal circulation to become part of the bile acid pool 
(Angulo, 2002). Oral absorption of UDCA occurs through bile acid solubilization 
(Lazaridis, Gores, & Lindor, 2001 ). UDCA is taken up from the portal blood into the 
liver with a first pass extraction of about 50%. UDCA is then conjugated with glycine 
and taurine and actively secreted into bile (Paumgartner & Beuers, 2002). During 
continuous UDCA treatment, 19-64% of the total bile acids become UDCA, and up to 
60% of the bile acids found in serum are UDCA depending on the daily dose used 
(Angulo, 2002). UDCA conjugates compete with endogenous bile acids for absorption in 
the ileum where they undergo enterohepatic circulation. The small amount of UDCA that 
is not absorbed in the terminal ileum is deconjugated in the colon and excreted in the 
feces. Less than 5% of the dose ofUDCA that is excreted is found in urine samples 
(Paumgartner & Beuers, 2002). 
1.2.2 Mechanism of Action. 
There are several proposed mechanisms of action that are felt to contribute to the 
hepatoprotective properties of UDCA. The most widely accepted mechanism of action is 
the protection of cholangiocytes against cytotoxicity of hydrophobic bile acids 
(Paumgartner & Beuers, 2002). This likely occurs through the displacement of 
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hydrophobic bile acids from the bile salt pool during competitive absorption ofUDCA in 
the ileum. 
Stimulation of hepatobiliary secretion is another important mechanism of action 
for UDCA. This mechanism is thought to occur by the stimulation of transporter proteins 
in the hepatocyte along with the insertion and targeting of transporter molecules in the 
canalicular membrane, ultimately preventing the accumulation and retention of toxic bile 
acids that may lead to hepatocellular injury (Cullen & Chapman, 2005). 
A third mechanism of action ofUDCA is the protection ofhepatocytes against 
bile acid induced apoptosis. Apoptosis is one of the main forms ofhepatocyte death in 
cholestatic liver disease and occurs through the accumulation of hydrophobic bile acids in 
hepatocytes (Lazaridis, Gores, & Lindor, 2001 ). UDCA appears to have an antiapoptotic 
effect signaling a survival mechanism in hepatocytes. This survival mechanism is 
thought to occur through the activation of epidermal growth factor receptor and mitogen-
activated protein kinases (MAPK) (Cullen & Chapman, 2005). Mitochondrial 
dysfunction by hydrophobic bile acids also leads to apoptosis. UDCA achieves 
cytoprotection to hepatocytes and cholangiocytes by preserving and stabilizing plasma 
membranes and mitochondria (Rodriques, Fan, & Wong, 1998). 
1.2.3 Treatment for Cholestatic Liver Disease. 
UDCA has been evaluated and is currently being used in several hepatocellular 
diseases especially those that cause cholestasis. One of the initial uses for UDCA was in 
gallstone dissolution. UDCA causes solubilization of cholesterol from the gallstone 
surface. Dissolution rates have been reported to be 30-60% (Tint, Salen, & Colalillo, 
-------------- ---------
1982). This treatment has fallen out of favor with the advent oflaparoscopic surgical 
procedures for cholecystectomy. UDCA is however, still used for high-risk surgical 
candidates (Angulo, 2002). 
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UDCA has been used in patients with cystic fibrosis (CF) who develop thick 
biliary secretions leading to biliary obstruction and potentially cirrhosis. Two studies 
have demonstrated improvement in biochemical and histological parameters when UDCA 
was used in this patient population. In 1998, Lindblad, Glaumann & Strandvik followed 
a cohort of CF patients with liver disease/cirrhosis based on liver biopsy. These patients 
received UDCA at a dose of 1 0-15mg/kg/day for two years. At the end of the study, the 
authors had shown statistically significant improvements in liver biochemistry and liver 
histology in the cohort, leading them to conclude that UDCA "modulates inflammation in 
CF-associated liver disease and indicates improvement in liver morphology during two 
years of treatment" (Lindblad, Glaumann, & Strandvik, 1998). In 1997, Van De 
Meeberg, et al; published an RCT in which thirty patients with CF and cholestatic liver 
disease were randomized to low dose (lOmg/kg/day, n =17) or high dose (20mg/kg/day, 
n= l3) UDCA. High dose UDCA produced a significant improvement and often 
complete response in liver biochemistry at two years compared to low dose UDCA. The 
authors concluded that because UDCA was so well tolerated, high dose UDCA should be 
the treatment of choice in this patient population (Van De Meeberg, Houwen, 
Sinaasappel, Heijerman, Bijleveld, & Vanberge-Henegouwen, 1997). 
UDCA has been used as treatment for intrahepatic cholestasis of pregnancy. This 
condition affects females who are usually in their third trimester of pregnancy. It is 
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characterized by severe pruritus and an increase in liver enzymes in a cholestatic pattern. 
This condition has led to increased fetal distress, premature delivery and an increased risk 
of perinatal mortality (Angulo, 2002). In 1997, Palma, et al; performed an RCT in which 
patients were randomized to one gram of UDCA or placebo. This study found that UDCA 
improved the clinical symptoms of pruritus and also improved liver tests in this patient 
population. In this study, deliveries occurred at or near term in the treatment group and 
occurred earlier in the placebo group (Palma, et al., 1997). 
Perhaps the greatest success of UDCA to date has been in patients with PBC. This 
is a cholestatic liver disease that shares some similarities to PSC. The disease most often 
occurs in middle-aged women and is characterized by destruction of small intralobular 
bile ducts and usually progresses to cirrhosis and liver failure ifleft untreated. There 
have been several well-performed RCT's that have demonstrated a survival benefit when 
UDCA was used in patients with PBC. In 1997 Poupon, et al; performed a combined 
analysis of the major RCTs using UDCA in patients with PBC. This analysis included a 
Canadian, French and Mayo clinic RCT. The results identified a survival benefit and a 
decreased need for liver transplant when UDCA was used for four years compared to 
patients receiving placebo, RR 1.9, 95% CI ( 1.3-2.8), p<0.01 (Poupon, Lindor, Cauch-
Dudek, Dickson, Poupon, & Heathcote, 1997). There have been three meta-analyses 
published to date looking at the use ofUDCA in PBC. Two ofthese studies did not 
reveal a survival benefit or a delay in time to transplant in PBC patients taking UDCA 
(Gong, Huang, Christensen, & Gluud, 2007), (Goulis, Leandro, & Burroughs, 1999). 
These two meta-analyses have been criticized for including studies with short duration of 
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follow up and for including studies using low doses ofUDCA. Shi et al, in a third meta-
analysis included only RCTs that had greater than two years of follow up and used doses 
ofUDCA greater than 10 mg/kglday. This meta-analysis showed a significant reduction 
in the incidence ofliver transplantation (OR 0.65, p=O.Ol). The authors concluded that 
long term treatment with mid dose UDCA can improve liver biochemistry and survival 
free of liver transplantation in patients with PBC (Shi, Wu, Lin, Chen, Zhu, & Xie, 2006). 
1.3 Statement of Problem 
It is not surprising that based on prior experience with UDCA in cholestatic liver 
disease, physicians would try this medication for patients with PSC. There have been 
several non-randomized and randomized trials that have set out to answer the question of 
whether UDCA is efficacious in the treatment of patients with PSC. Many of these trials 
have recruited small numbers of patients, likely because ofthe low incidence of this 
disease in the population. Many trials used varying doses ofUDCA in their protocols. 
These studies have displayed conflicting results. The question of whether UDCA 
prolongs survival or time to transplant in patients with PSC remains to be answered. 
1.4 Meta Analysis 
1.4.1 Objectives and Rationale. 
A meta-analysis may be helpful in determining the usefulness of UDCA in 
patients with PSC. A meta-analysis critically reviews and statistically combines results 
of previous research. This type of study may add to our current knowledge of a given 
topic by providing a more precise estimate of the true effect than any one individual study 
(Tonelli, Hackam, & Garg, 2009). Sacks, et al; have outlined the main purposes and 
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strengths of a meta-analysis: 1) to increase statistical power for primary endpoints and for 
subgroups, 2) to resolve uncertainty when reports disagree, 3) to improve estimates of 
effect size, 4) to answer questions not asked at the start of a trial (Sacks, Berrier, 
Reitman, Ancona-Berk, & Chalmers, 1987). Using these criteria, it seems fitting that a 
meta-analysis may be used to answer a question such as "Does UDCA prolong survival 
in patients with PSC?" 
1.4.2 Design and Interpretation. 
There are two main aspects to consider in the design and interpretation of a meta-
analysis. The first is the quantitative portion that deals with statistically combining 
results from individual trials. This is a very important part of the meta-analysis; however, 
the trials should not be combined unless their outcomes are similar enough to pass a 
statistical test of heterogeneity. If heterogeneity exists between the outcomes of the trials, 
the studies should be examined carefully to try and identify why the outcomes are not 
similar enough to be statistically combined (Hardy & Thompson, 1998). Occasionally 
reasons for heterogeneity are identified and a meta-analysis can still be performed 
through subgroup analysis of the included trials. 
The second equally important component to the meta-analysis is the qualitative 
portion. A meta-analysis is much more robust if the author has investigated and 
described the study quality of each individual trial. It is important to record quality 
indicators such as whether randomization was complete, was blinding performed, were 
patients analyzed in an intent to treat fashion and was follow up adequate. The more 
information recorded in a trial the more robust the data ultimately leading to a stronger 
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study. Guidelines have been published to evaluate the quality of a meta-analysis. A high 
quality meta-analysis would provide positive answers for the following questions: 1) Is 
there evidence of a working protocol, 2) Are literature search strategies explicitly 
described, 3) Are inclusion and exclusion criteria specified, and reasons given for 
exclusions, 4) Are visual displays and tests of homogeneity done, 5) Are appropriate 
statistics and sensitivity analysis employed, 6) If the pooled analysis shows significant 
differences, is the issue of publication bias addressed, 7) Are conclusions drawn for 
treatment recommendations (L'abbe, Detsky, & O'Rourke, 1987). 
1.5 Research Objectives 
Using the above guidelines, a meta-analysis will be performed to achieve the 
following research objectives: 
1) Determine if UDCA prolongs survival in patients with PSC. 
2) Identify whether there is a survival advantage for using high dose 
(> 15 mglkglday) UDCA in patients with PSC. 
3) Determine ifUDCA prevents worsening of liver histology in patients with 
PSC. 
4) Identify whether UDCA decreases the need for liver transplantation in patients 
with PSC. 
5) Determine the usefulness of the surrogate markers AST, ALP, albumin, and 
bilirubin, for predicting hard outcomes such as mortality or need for liver 
transplant in patients with PSC. 
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6) Explore the role of using standardized mean difference as an effect measure in 
meta-analysis for continuous outcome measurements. 
1.6 Research Question 
In order to accomplish the research objectives, a meta-analysis will be conducted 
to answer the primary research question, 
"Does UDCA prolong survival in patients with PSC?" 
A meta-analysis will be conducted to answer the following secondary research 
questions: 
1) Does UDCA prevent the worsening of liver histology in patients with PSC? 
2) Using subgroup analysis, does high dose (>15mglkglday) UDCA offer a 
survival advantage over low/standard dose ( 1 0-15mg/kglday) UDCA in 
patients with PSC? 
3) Does UDCA decrease the need for liver transplantation in patients with PSC? 
4) In patients with PSC, do the liver enzymes ALP and AST significantly 
improve with UDCA compared to placebo? 
5) In patients with PSC, do the liver functions albumin and bilirubin significantly 
improve with UDCA compared to placebo? 
6) Does an improvement in surrogate markers such as liver enzymes and liver 
function correlate with a decrease in mortality or a need for liver 
transplantation in patients with PSC who are taking UDCA? 
Chapter 2 
Methods 
This chapter will focus on the methodology used to perform this meta-analysis. 
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Details of the literature search as well as the inclusion and exclusion criteria will be 
provided. The outcome measurements used in this meta-analysis will be listed. The 
method of assessing study quality will be explored. The details of the data abstraction to 
help determine if the outcome measurements are combinable will be presented. The 
statistical methods used for combining the results and determining outcome 
combinability will be provided. 
2.1 Literature Search 
The randomized controlled trials (RCTs) used in this meta-analysis were 
identified through a comprehensive literature search process. PubMed, Embase, the 
Cochrane library and Cinahl were the databases used for the literature search. Key words 
searched included primary sclerosing cholangitis, PSC, cholangitis, bile acids, 
ursodeoxycholic acid, ursodiol and UDCA. Limits placed on the search included clinical 
trials, randomized controlled trials, meta-analysis, human studies. All years and 
languages were included in the analysis. The reference section of each relevant study 
was reviewed in order to ensure that no RCTs were missed during the initial database 
search. 
The abstracts for all major gastroenterology conferences were searched in an 
attempt to identify unpublished trials that were available in abstract form. The major 
conferences included, Canadian Digestive Diseases Week (CDDW), Digestive Disease 
Week (DOW), United European Gastroenterology Week (UEGW) and the American 
College of Gastroenterology (ACG) Annual Scientific Meeting. These abstracts were 
manually searched from 1990-2009. 
2.2 Inclusion Criteria 
22 
In order to meet inclusion criteria for this meta-analysis, the studies had to be 
RCTs that were fully published. Each RCT required a treatment arm (UDCA) and a 
placebo group used for comparison. It was decided a priori that published abstracts of 
RCTs would be included in the meta-analysis but would be pooled separately as part of a 
sensitivity analysis to minimize bias in the meta-analysis. 
2.3 Exclusion Criteria 
Studies were excluded from this analysis if they were not RCTs or if there was no 
placebo group. Studies were excluded if their outcome measurements did not include at 
least one of the outcome measurements used for this meta-analysis. 
2.4 Outcome Measurements 
The primary outcome measurement used for this meta-analysis was overall 
mortality. Secondary outcome measurements included worsening of liver histology, need 
for liver transplant, and changes in the liver enzymes (AST, ALP) and liver function 
(bilirubin, albumin). 
2.5 Study Quality 
The quality of each study was assessed using a protocol developed by Jadad 
(Jadad, et al., 1996) (Appendix I). This scoring system has been validated as appropriate 
for determining the methodological quality of individual trials. In fact, it has become the 
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most widely used scoring system in the world for determining the quality oftrials 
(Haynes, Sackett, Guyatt, & Tugwell, 2008). Jadad, et al; have modified more lengthy 
protocols to include three key elements (randomization, blinding and withdrawals) that 
can be applied to RCTs and used to assess their overall methodological quality. The goal 
of the authors was to create a scoring system that could be used to assess a trials quality 
in a quick and efficient manner. The scoring system allocates a minimum score of zero 
and a maximum score of five. A trial with a score of less than three is felt to be of poorer 
quality and should be interpreted with caution. The benefit of the Jadad scoring system is 
that it is easy and quick to use. There are only five questions to answer in the scoring 
system. The protocol is, however, not without its criticism. Some authors believe that it 
is an oversimplified approach to determining methodological quality and that too much 
emphasis is placed on blinding (Berger, 2006). 
2.6 Data Abstraction 
Two independent critical appraisers (JF, SG) evaluated the assessed studies. Each 
evaluator was given a data abstraction sheet (appendix II) and Jadad's scoring system was 
applied for each study. Once a study was deemed appropriate for inclusion into the meta-
analysis, a quality score from 0-5 was determined and the average of the two scores was 
taken as the final score. If the two appraisers had different viewpoints about a certain 
trial, discussion occurred and results were compared before a consensus was finally 
reached. 
The key data collected included the dose of UDCA used, either at standard dosing 
of 1 0-15mg!kg/day or high dosing of > 15mg/kg/day. The appraisers sought to determine 
--------------------------------
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not only whether randomization was carried out but how was it accomplished. Each trial 
was assessed for blinding and whether appropriate follow up was performed. The 
reviewers determined if all patients were accounted for at the end of the trial. The 
primary outcomes of each study were noted. Baseline characteristics recorded included 
demographics such as average age, gender, and percent of patients with underlying IBD. 
Baseline liver function and biochemistry was recorded and compared to the liver function 
and biochemistry at the end of the trials. 
When important information was not available but the study was deemed 
appropriate for the meta-analysis, attempts were made to contact the study authors for 
more information. 
2. 7 Combinability of Results 
Each trial deemed appropriate for the meta-analysis was checked for similarities 
by comparing the study protocols and study populations. Appraisers manually checked 
the outcome measurements to determine combinability. The study drug was also 
assessed for homogeneity by determining if the dosage of UDCA was the same 
throughout all trials. 
Statistical combinability was determined by formally checking for homogeneity of the 
outcomes in the trials. This was carried out by using a chi-square (X2) statistic for 
heterogeneity. The trials were felt to be combinable if the p-value for the statistical test 
for heterogeneity was >0.1 0. If the analysis showed heterogeneity, the individual studies 
were examined for their differences. The x2 test for heterogeneity is useful to serve as an 
indicator that the differences between trials may be due to more than just chance alone. 
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Attempts to explain the heterogeneity will be detailed when necessary. Sub group 
analysis will be attempted if differences in trials are felt to be clinically significant for the 
analysis. 
2.8 Combining the Results 
The data (liver biochemistries and liver function) from the trials were combined 
by calculating standardized mean differences (SMD) for each trial and then determining a 
pooled estimate of the SMD along with the 95% confidence interval (CI) for the pooled 
SMD. A p-value of <0.05 was determined to be statistically significant. Statistical 
analysis for the pooled SMD and 95% CI were carried out using Comprehensive Meta-
Analysis Volume 2 (CMA) (Borenstein, Hedges, Higgins, & Rothstein, 2005). 
Outcomes such as mortality, liver histology, and need for liver transplant were 
combined using a pooled estimate of the odds ratio and the 95% CI was then calculated 
for the pooled estimate of the odds ratio using CMA. A p-value of <0.05 was determined 
to be statistically significant. 
There are two models used in meta-analysis to determine a combined effect size 
for the outcome of interest. The fixed effects model assumes that there is one effect size 
that is shared by all studies. The statistical pooling of the outcome leads to the estimate 
for this common effect size. In a fixed effects model, the only error in the estimate of the 
combined effect is the random error within each RCT (Spector & Thompson, 1991 ). This 
method of producing a combined effect size and confidence interval is often referred to as 
the liberal method and assumes that the trials are homogenous enough to be combined for 
analysis. 
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The other model used in meta-analysis is the random effects model which 
assumes that the true effect may vary from trial to trial. In this model there is not only 
variation within each trial but also variation between trials as well (Spector & Thompson, 
1991 ). This model is often referred to as more of a conservative model. In the absence of 
heterogeneity, the fixed effects model and random effects model will often approximate 
each other (Alderson & Green, 2002). When a meta-analysis includes only a few trials, it 
is difficult to calculate the between trial variation and this model is not recommended for 
use. (Borenstein, Hedges, & Rothstein, 2007). 
This current meta-analysis used a fixed effects model to determine the combined 
effect size for the various outcome measurements. If heterogeneity between the trials was 
discovered, attempts were made to resolve this heterogeneity. If the trials were felt to be 
combinable despite quantitative heterogeneity then a fixed effects model was still used 
because the small number of trials included in this meta-analysis would limit the ability 
of a random effects model to detect between trial variation. 
··-----------------------------------------------------------
Chapter 3 
Results 
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ln this chapter, the results of the literature review will be revealed and a 
qualitative analysis of the included RCTs will be performed. The RCTs will be compared 
in terms of overall quality, patient characteristics, trial methodology and outcome 
measurements. 
A quantitative analysis of the included RCTs will be performed. The RCTs will 
be combined when appropriate to determine a pooled effect size and 95% CI for each 
outcome measurement. A sensitivity analysis will be conducted for statistically 
significant results between treatment groups. 
3.1 Literature Review 
A total of fifteen fully published studies were identified during the literature 
review. Although all languages were included in the review of the literature, all 
published studies suitable for this meta-analysis were written in English. Only six of 
these studies were fully published RCTs comparing UDCA versus placebo in patients 
with PSC (Beuers, et al. , 1992), (Lindor, 1997), (Mitchell, Bansi, Hunt, Von Bergmann, 
Fleming, & Chapman, 2001), (Stiehl, Walker, Stiehl, Rudolph, Hofmann, & Theilmann, 
1994), (Olsson, et al., 2005), (Lindor, et al., 2009). Another study was deemed suitable 
for the meta-analysis; however, there was no end point data listed in the published trial 
that could be used for this meta-analysis (De Maria, Colantoni, Rosenbloom, & Van 
Thiel, 1996). The principal investigator was contacted but did not respond to our request 
for more data. Three studies were excluded after it was determined that they compared 
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single dose UDCA to multi-dose UDCA in patients with PSC (Podda, et al. , 1989), (Van 
de Meeberg, et al. , 1996), (Van Hoogstraten, et al., 1998). One trial was excluded as it 
compared low dose UDCA, standard dose UDCA and high dose UDCA with no placebo 
group for comparison (Cullen, Rust, Flemming, Edwards, Beuers, & Chapman, 2008). 
Two pilot studies were not randomized and were therefore excluded from this meta-
analysis (Harnois, Angulo, Jorgensen, LaRusso, & Lindor, 2001 ), (O'Brien, Senior, 
Arora-Mirchandani, Batta, & Salen, 1991). Two meta-analyses were discovered during 
the literature search. A meta-analysis ofbile acid therapy in PSC was found in the 
Cochrane library and was published the same year that this meta-analysis was initially 
presented (Chen & Gluud, 2003), (Gruchy & Fardy, 2003). Another meta-analysis 
published in 2009 was identified after this current meta-analysis was completed (Shi, Li, 
Zeng, Lin, & Xie, 2009). The results will be reviewed and compared to this current meta-
analysis in the discussion section. 
The extended literature review, that included a review of the references for the 
relevant RCT's and searching the abstracts of all major gastrointestinal meetings in North 
America and Europe, identified five abstracts that might be suitable for our meta-
analysis. After careful review ofthe published abstracts, we determined that two of the 
studies were not RCTs (Kim, Jorgemsen, Malinchoc, Benson, Dickson, & Lindor, 1997), 
(O'Brien, Craig, & Hatfield, 1993). Two studies were abstracts of preliminary results 
from fully published trials that have been reviewed and abstracted for consideration in 
this meta-analysis (Bansi, Christie, Fleming, & Chapman, 1996), (Van Thiel, Wright, & 
Gavaler, 1992). One abstract was deemed suitable for this meta-analysis; however, after 
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extensive investigation, we could not identify the necessary data for entry into the meta-
analysis (Lo, et al., 1992). Our literature review could not determine whether this 
abstract was ever published as a full publication. 
3.2 Quality of Studies 
The quality of each of the six randomized controlled trials was assessed by the 
method previously outlined (Jadad, et al. , 1996) (Appendix 1). This method relies on 
explicit detail in the methodology section of each publication. It is difficult to accurately 
assign quality scores to abstracts given their inherent lack of detail. The quality scores of 
each ofthe six fully published RCT's are found in Table 3.1. A score between four and 
five in the Jadad system is generally felt to be of good methodological quality. A study 
with a quality score of three or less is felt to have some methodological flaws. Table 3.2 
outlines the scores for the individual questions in each trial. The outline of the scoring 
system draws the readers' attention to the fact that the randomization and blinding 
processes are the main focus of this quality system. It is possible that important trial 
methodology may be underestimated in such a scoring system. 
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Table 3.1 
Code Numbers and Quality Scores For Published 
Author Code Quality Number Score a 
Fully Published Trials 
Beuers, U; et al. 1992 F1 5/5 
Lindor, K.D; et al. 1997 F2 4/5 
Mitchell, S.A; et al. 2001 F3 4/5 
Stiehl, A; et al. 1994 F4 3/5 
Olsson, R; et al. 2005 FS 4/5 
Lindor, K.D; et al. 2009 F6 5/5 
Abstract Only 
Randomized Controlled Trials 
Lo, S.K; et al. 1992 A1 3/5 
aJadad Scoring System (see appendix I) 
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Table 3.2 
Detailed Quality Scores For Each Trial 
F1 F2 F3 F4 FS F6 A1 
Was the study 1 1 1 1 1 1 1 
randomized? 
Was the method used to 1 1 0 1 0 1 0 
generate the sequence of 
randomization described 
and appropriate? 
Was the study double 1 1 1 1 1 1 1 
blind? 
Was the method of 1 1 1 0 1 1 0 
double blinding described 
and appropriate 
Was there a description 1 0 1 0 1 1 1 
of withdrawals and 
dropouts? 
Inappropriate n/a n/a n/a n/a n/a n/a n/a 
randomization 
(-1 point) 
Inappropriate blinding n/a n/a n/a n/a n/a n/a n/a 
(-1 point) 
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3.3 Comparability of Patients Studied 
The patient characteristics for the included trials are outlined in table 3.3. Patients 
with PSC are typically younger males who often have underlying inflammatory bowel 
disease (IBD). The age range for patients in these six trials is 38.5-52.0. The subtle 
difference in ages amongst the six trials may represent patients that are at different stages 
of disease. The majority of patients in the included trials are males with IBD. Four out 
of six trials (Fl , F2, F3, F6) identify a majority of patients who are at stage I or II liver 
disease at entry into the trial. Trial F4 appears to have patients who have more advanced 
disease as 65% of patients already have stage III-IV liver disease at the onset of the study. 
Trial F5 does not include histological staging in their study. Without knowing the results 
of the trials, one might speculate that patients in the trial F4 may not have a response to 
UDCA since patients are already at an advanced histological stage and therefore the 
damage to the liver from PSC may be irreversible at that point. However, it is difficult to 
assess the severity of disease through biopsy alone in any individual patient as the disease 
is patchy and any one patient may have random biopsies showing anything from normal 
bile ducts to frank cirrhosis (Cullen & Chapman, 2005). 
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Table 3.3 
Patient Characteristics 
Trial Mean Male(%) IBD{%) Histologic Stage Number(%) 
Number Age 
II Ill IV 
F1 38.8 79 71 28.5 28.5 28.5 14.3 
F2 42.8 58 81 18.5 30.5 33.5 18 
F3 52.0 73 77 27.0 19.2 42.3 11.5 
F4 38.5 Not listed 85 35 45.0 20.0 
FS 43.3 70 85 
F6 46.6 57 77 33.5 26.5 24.5 15.5 
Note: IBD =Inflammatory bowel disease 
---------------------------------------------------
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3.4 Comparability of Randomized Controlled Trials 
Clinical characteristics of the six trials are outlined in table 3 .4. There is a large 
range in the size of the various trials, which is skewed towards the three larger trials that 
recruited 198 (F5), 150 (F6) and 105 (F2) patients each. The other three trials have much 
fewer patients. The overall effect size of the different outcome measurements for this 
meta-analysis will ultimately be impacted with a bias toward the larger trials. 
Another important difference between the trials may be the dosage of UDCA 
used. Many experts believe that high dose UDCA (> 15mg!kglday) will have a greater 
impact on patients with PSC than using lower dosing ( 1 0-15mglkglday). Three trials 
(F3), (F5) and (F6) used high dose UDCA and met the criteria for inclusion in this meta-
analysis. The remainder of the trials all used dosing <15mglkglday. 
There was also a wide variety in the total duration of the RCTs. The recruitment 
phase of the trials lasted anywhere between three months and six years. Although one 
trial (F4) lasted only three months for the placebo-controlled portion of the study, the 
authors continued to follow patients for three years to determine the effect ofUDCA on 
their outcome measurements. The ethical guidelines determined that this trial had to end 
after three months because there was a greater than two fold increase of serum 
transaminases in 80% of patients in the placebo group. All trials were similar in total 
length of follow up except for F5 and F6, which had a longer follow up (five years). 
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Table 3.4 
Characteristics of Individual Trials 
Trial Number Dosage of Dosing Follow up Length of Duration 
of UDCA (Single or Intervals Follow up of Trial 
Patients Multidose) (months) (months) (months) 
in Trial 
F1 14 13-15 Multidose 6 12 12 
mg/kg/day 
F2 105 13-15 Multidose 3 24 72 
mg/kg/day 
F3 26 20 Multidose 3 24 24 
mg/kg/day 
F4 20 750mg/day Single 3 36 3 
F5 198 17-23 Multidose 6 60 60 
mg/kg/day 
F6 150 28-30 Multidose 3 60 72 
mg/kg/day 
Note: UDCA = Ursodeoxycholic acid 
3.5 Comparability of Outcomes 
The outcome measurements used in the included RCTs are listed in table 3.5. 
The effect size for the outcome measurements overall mortality, worsening of liver 
histology and liver transplant required was analyzed by calculating odds ratios. 
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The odds of death in the treatment group as compared to the placebo group, the 
odds of developing worsening liver histology in the treatment group as compared to the 
placebo group and the odds of requiring a liver transplant in the treatment group as 
compared to the placebo group were all calculated. These odds ratios and respective 95% 
CI were calculated as outlined in Appendix III. These odds ratios were then combined to 
give an overall pooled odds ratio and 95% CI for each dichotomous outcome 
measurement. 
The odds ratio for each of the dichotomous outcomes along with their 95% Cis in 
the RCTs were tabulated in tables 3.6-3.9 and shown graphically in figures 3.1-3.4. 
These tables and figures also show the overall odds ratio for each dichotomous outcome 
along with its 95% Cl. 
Liver biochemistry results were analyzed by calculating an overall standardized 
mean difference (SMD) to allow for differences in laboratory values between the various 
studies. The mean values pre and post treatment for AST, ALP, bilirubin and albumin 
along with their standard deviations were used to calculate SMD's as outlined in 
Appendix III. These SMD's were then combined to give an overall pooled SMD and 95% 
CI. 
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The SMD's for each of the biochemical outcomes along with their 95% CI's in 
the trials were tabulated in Tables 3.10-3.13 and shown graphically in figures 3.5-3.8. 
These tables and figures also show the pooled SMD for each biochemical outcome with 
its 95% CI. 
Table 3.5 
Comparability of Outcome Measurements 
RCT 
Fl 
F2 
F3 
F4 
FS 
F6 
Liver 
Enzymes/ 
Function 
Histology Endoscopic 
Abnormalities 
(ERCP) 
Death Liver 
Transplant 
Required 
Note: RCT =Randomized Controlled Trial; ERCP= Endoscopic Retrograde 
Cholangiopancreatography; UDCA = Ursodeoxycholic Acid 
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Tolerability 
of UDCA 
3.6 Outcome Measurements- Pooling of Data and Exploration of Heterogeneity 
3.6.1 All Cause Mortality. 
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Five of the fully published trials listed overall mortality as an outcome 
measurement (Fl,F2,F3,F5,F6). Examining figure 3.1, the forest plot demonstrates that 
four trials favored UDCA, while one trial (F6) favored placebo. The confidence intervals 
were large and they all crossed l. None of the trials showed a significant difference 
between the UDCA group and the placebo group in terms of overall mortality and there 
was considerable overlap of the confidence intervals. The fixed effects model calculated 
a pooled odds ratio of0.859 with 95% CI (0.365-2.022) and a non-significant p-value of 
0.728 (table 3.6). As previously outlined, RCTs studying uncommon diseases require 
large numbers of patients in order to detect a difference in treatment groups for a rare 
outcome such as mortality. In this situation, the larger the study, the more events of 
interest occur resulting in a smaller confidence interval and a higher likelihood of 
achieving a statistical difference amongst treatment groups if a difference were truly 
present. 
The formal test of heterogeneity (Appendix III) for this outcome yields a Q value 
of 1.480, with four degrees of freedom ( df=4) and a p-value of 0.830. This would 
indicate that the trials are homogeneous for the outcome in question and are able to be 
combined. 
In order to determine if the cause of overall mortality was related to the disease, 
study drug or another confounder, the specific cause of death in each patient needs to be 
examined. The overall mortality in the UDCA group was ten out of two hundred and 
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forty five patients. Five patients died of cholangiocarcinoma, a known complication from 
PSC, and five patients died of liver decompensation that can be explained from end stage 
liver disease secondary to PSC. In the placebo group twelve out of two hundred and forty 
eight patients died. Six patients died of cholangiocarcinoma, five died from liver 
decompensation and one person died from a cause listed as being unrelated to liver 
disease. This analysis would suggest that the mortality rates in both groups are likely 
attributable to having PSC and confounders are less likely. This is not surprising for this 
group of patients who tend to be younger and have less co-morbidities. 
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Table 3.6 
Outcome Measurement- Overall Mortality 
RCT 
F1 
F2 
F3 
F5 
F6 
Overall 
UDCA 
(n/nt) 
0/6 
~3 
0/13 
2/97 
5/76 
10/245 
Placebo Model 
(n/nt) 
l/8 
4/52 
l/13 
~101 
~4 
12/248 Fixed 
OR Lower Upper P-value 
95% Cl 95% Cl 
0.385 0.013 11.168 0.578 
0.720 0.153 3.387 0.678 
0.309 0.011 8.300 0.484 
0.688 0.112 4.208 0.685 
1.667 0.384 7.239 0.495 
0.859 0.365 2.022 0.728 
Note: RCT = Randomized controlled trial; UDCA = Ursodeoxycholic acid; njnt = 
Number of patients affected with the outcome divided by the total number of 
patients in the group; OR = Odds ratio 
Studynarm Outcorre Events I Total Odds ratio and 95% Cl 
UDCA Placebo 
Mtchell, 2001 ACM 0/13 1 I 13 
Undor, 1997 ACM 3/53 4/52 
Undor, 2009 ACM 5/76 3/74 
Osson, 2005 ACM 2/97 3/ 101 
Beuers, 1992 ACM 0/6 1/8 
10/24512/248 
0.01 0.1 1 10 100 
Favours UDCA Favours Placebo 
Note: ACM =All Cause Mortality; UDCA = Ursodeoxycholic Acid 
Figure 3.1: A Forest Plot; Using Odds Ratio and 95% Cl, 
Comparing All Cause Mortality in PSC Patients Receiving 
U DCA or Placebo. 
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3.6.2 Sub Group Analysis- All Cause Mortality. 
Once the analysis determined that there was no statistically significant difference 
between the UDCA group and placebo group in terms of the primary outcome of overall 
mortality, the data was closely inspected in order to determine ifthere was a specific sub 
group that may have a survival advantage from receiving UDCA. The RCTs were fairly 
homogenous in most baseline characteristics apart from the dose ofUDCA that each trial 
used. Perhaps there was a difference in overall mortality between patients taking high 
dose UDCA (> l5mglkglday) and those taking low/standard dose UDCA ( 10-
15mglkglday). 
A subgroup analysis arranged by dosing ofUDCA was analyzed for the outcome 
of overall mortality. Three RCTs used high dose UDCA (F3,F5,F6) and two RCTs used 
low/standard dose UDCA (F1 ,F2). Figure 3.2 demonstrates a forest plot for this 
particular outcome. The graph demonstrates that in the high dose UDCA subgroup, two 
trials favor UDCA while one trial favors placebo. The CI 's are large and they all cross 1. 
The fixed effects model for the subgroup of high dose UDCA calculated a pooled odds 
ratio of 1.017 with 95% CI (0.346-2.987) and a non-significant p-value of 0.976 (table 
3.7). The formal test of heterogeneity (Appendix III) for the sub group of high dose 
UDCA for the outcome overall mortality yields a Q value of 1.118 with two degrees of 
freedom (df-=2) and a p-value of0.572. 
The forest plot (figure 3.2) demonstrates that in the low/standard dose UDCA 
subgroup, both trials favor UDCA, although the CI's are large and both cross 1. The 
fixed effects model for the subgroup of high dose UDCA calculated a pooled odds ratio 
,-----------~------------- -
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of 0.645 with 95% CI (0.158-2.635) and a non-significant p-value of0.542 (table 3.7). 
The formal test of heterogeneity (Appendix III) for the sub group of low/standard dose 
UDCA for the outcome overall mortality yields a Q value of 0.110 with one degree of 
freedom (df=l) and a p-value of0.740. This subgroup analysis suggests that there is no 
difference between UDCA and placebo in overall survival regardless of the dosing of 
UDCA administered. 
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Table 3.7 
Overall Mortality in PSC Patients Receiving UDCA or 
Placebo, Subgroup Analysis According to UDCA Dosing 
Model For 
Meta 
Analysis 
Fixed 
Subgroup RCT 
(UDCA 
Dosing) 
low/Std F1 
Dose 
low/Std F2 
Dose 
Low/Std 
Dose 
High Dose F3 
High Dose F5 
High Dose F6 
Fixed High Dose 
UDCA 
(n/nt) 
0/6 
¥53 
~9 
0/13 
2/97 
5/76 
7/186 
Placebo OR 95% Cl P-value 
(n/nt) 
ll Ul 
1/8 0.385 0.013 11.168 0.578 
0.720 0.153 3.387 0.678 
~0 0.645 0.158 2.635 0.542 
1/13 0.309 0.011 8.300 0.484 
¥101 0.688 0.112 4.208 0.685 
?/74 1.667 0.384 7.239 0.495 
7/188 1.017 0.346 2.987 0.976 
Note: UDCA = Ursodeoxycholic Acid; low fstd = low and standard dosing; RCT= 
Randomized controlled trial; nfnt = Number of patients affected with the outcome 
divided by the total number of patients in the group; 
OR= Odds ratio; LL = lower limit; UL = Upper limit 
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Cl'!1!J!!!t: Sluttrame S!.l!sro<91MttinSIUtt ~ Everls / "bal Qldo ralloard 95'Jio a 
Slbg'cq> 1Mttin slutt 
lllCA Placebo 
H!7>Dose Undc>'. 2009 Hi7> Dose A().1 5/ 76 3/ 74 
H!7>Dose Michell. 2001'1!1> Dose Ao.1 0/ 13 1/ 13 
HghOose Osson. 2005H!1> Dose Ao.1 2/ 'I/ 3/ 101 
Hgh Dose 7/186 7/ 188 
LoWSia'<lafdOose Beuers, 1992loYIStardard Dose A().1 0/ 6 1/8 
LoWSia'<lardOose Undc>'. 1997 LoWSiardard Dose ACM 3/ 53 4/ 52 
L!M/Sia'<lardOose 3/ 59 5/ f1J 
0.1 10 100 
Fai.UI'S Placel:x> 
Note: ICM =AI Cause Mlrtality; UDCA= Ursodeoxycholic lcid 
Figure 3.2: A Forest Plot; Using Odds Ratio and 95% Cl, 
Comparing All Cause Mortality in PSC Patients Receiving 
UDCA or Placebo, Stratified According to UDCA Dosing. 
47 
3.6.3 Worsening of Liver Histology. 
Three of the fully published trials listed worsening of liver histology as an 
outcome measurement (FI,F2,F3). Two ofthe three trials (FI,F3) demonstrated a non-
significant trend toward favoring the UDCA treatment group for improvement in liver 
histology. However, one trial (F2) demonstrated a trend toward worsening of liver 
histology in the UDCA group, although this trend was non-significant. Figure 3.3 
demonstrates a forest plot for this particular outcome. The graph shows some degree of 
heterogeneity amongst the groups. The formal test ofheterogeneity (appendix III) for 
this outcome yields a Q-value of 6. 731, which with two degrees of freedom ( df=2), leads 
to a p-value of0.035. The point estimate for the odds ratio of worsening liver histology in 
the UDCA group as compared to the placebo group is 0.903 using a fixed effects model 
with a 95% CI (0.316-2.582) and non significant p-value of0.849 (table 3.8). The small 
overall sample size, 67 patients in each group, may not be enough patients needed to 
detect a significant difference amongst treatment groups thus leading to a potential type II 
error. 
The trials need to be examined in more detail to explain the potential 
heterogeneity. Two trials used the previously described Ludwig system for staging liver 
disease in patients with PSC (F2,F3). The third trial (Fl) used a scoring system 
introduced by Poupon for staging patients with liver disease (Poupon, Balkau, Eschwege, 
& Po upon, 1991 ). All trials used a similar blinding system so that the pathologists were 
unaware of the treatment group the specimen belonged. The pathologist was also 
unaware of whether the liver biopsy was pre or post treatment in all studies. Only one 
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RCT (F3) used two pathologists who read all biopsies to decrease bias and improve 
quality control. Two trials (F2,F3) had biopsies analyzed at 24 months whereas one trial 
(F 1) analyzed liver biopsies at 12 months. The difference in grading system may 
obviously introduce heterogeneity amongst the trials. The timing of liver biopsy may 
also introduce heterogeneity if the effect ofUDCA on liver histology is more pronounced 
the longer the drug is administered to patients. However, this doesn't fully explain the 
results seen in this meta-analysis as the trial with the most patients and the longest follow 
up (F2), amongst the trials measuring histology as an outcome, was the trial that did not 
favor an improvement in liver histology for the UDCA group. 
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Table 3.8 
Outcome Measurement- Worsening of Liver 
Histological Stage 
RCT UDCA Placebo Model OR Lower Upper P-value 
(n/nt) (n/nt) 95%CI 95%CI 
F1 4/6 0.125 0.008 1.998 0.141 
F2 &151 ~1 2.977 0.742 11.942 0.124 
F3 2/11 5/10 0.222 0.031 1.595 0.135 
Overall 1~7 12/67 Fixed 0.903 0.316 2.582 0.849 
Note: RCT = Randomized controlled trial; UDCA = Ursodeoxycholic acid; nfnt = 
Number of patients affected with the outcome divided by the total number of 
patients in the group; OR= odds ratio 
Study name Outcome Events/ Total 
UDCA Placebo 
Mitchell,2001 WLH 2/11 5/10 
Undor, 1997 WLH 8/51 3/ 51 
Beuers, 1992 WLH 1 I 5 4/6 
11 /6712/ 67 
Odds ratio and 95%0 
0.01 0.1 10 100 
FavOIIS lDCA FavOIIS Placebo 
Note: WlH =Worsening UYI!I' Histology; UDCA= Ursodeoxycholic lcid 
Figure 3.3: A Forest Plot; Using Odds Ratio and 95% Cl, 
Comparing the Occurrence of Worsening Liver Histology 
in PSC Patients Receiving UDCA or Placebo. 
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3.6.4 Liver Transplant Required. 
Four of the fully published trials listed a need for liver transplant as an outcome 
measurement (F2,F3,F5,F6). Three of the four trials (F2,F3,F6) demonstrated a non-
significant trend toward an increased odds of requiring a liver transplant for the UDCA 
group; while one trial (F5) demonstrated a non-significant trend toward a decreased odds 
of requiring a liver transplant for the UDCA group. Figure 3.4 demonstrates a forest plot 
for this particular outcome. The fonnal test of heterogeneity (appendix Ill) for this 
outcome yields a Q-value of2.922, with three degrees of freedom (df=3) and a p-value of 
0.404. This would indicate that the trials are homogenous for the outcome in question and 
are able to be combined. 
The point estimate for the odds ratio of requiring a liver transplant in the UDCA 
group as compared to the placebo group is 1.243 using a fixed effects model with a 95% 
CI (0.667-2.317) and non significant p-value of 0.494 (table 3.9). These results would 
suggest that UDCA does not decrease the need for liver transplant in patients with PSC. 
An alternative theory is that there are not enough patients requiring liver transplant in this 
meta-analysis to detect a significant difference between the treatment groups. 
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Table 3.9 
Outcome Measurement- Liver Transplant Required 
RCT UDCA Placebo Model OR Lower Upper P-value 
(n/nt} (n/nt} 95% 95% 
Cl Cl 
F2 9,/S3 &'52 1.125 0.398 3.183 0.824 
F3 1/13 0/13 3.240 0.120 87.125 0.484 
F5 5/97 &'101 0.632 0.199 2.003 0.435 
F6 11/76 5/74 2.335 0. 770 7.087 0.134 
Overall 2&'239 21/240 Fixed 1.243 0.667 2.317 0.494 
Note: RCT = Randomized controlled trial; UDCA = Ursodeoxycholic acid; 
njnt = Number of patients affected with the outcome divided by the 
total number of patients in the group; OR = Odds ratio 
Study name rucome Events/ Total Odds ratio and 95% a 
liX:A Placebo 
M~chell, :ID1 LlR 1/13 0/ 13 
urm, 1997 LlR 9/53 8/ 52 
urm, 20C9 LlR 11/76 5/74 
Olssrn, 2roi LlR 5/ r;n 8/ 101 
26 / ZfJ 21 I 240 
0.01 0.1 1 10 100 
FavOI.I'S lDCA Favours Placebo 
~: LlR: Uver Transplant Received; lDCA = lksodeoxycholic Acid 
Figure 3.4: A Forest Plot; Using Odds Ratio and 95% Cl, 
Comparing the Requirement of Liver Transplantation in 
PSC Patients Receiving UDCA or Placebo. 
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3.6.5 Albumin. 
Three of the six fully published trials listed results for the liver function albumin 
to be analyzed in this meta-analysis (F2,F3,F4). Examining Figure 3.5, we can see that 
two of the trials (F2,F3) show a treatment effect favoring UDCA; while one trial (F4) 
demonstrates a treatment effect favoring placebo. Unfortunately, the treatment effect in 
the trials is small resulting in large 95% CI which cross 1. There are only three trials 
listing albumin as an outcome measurement and therefore pooling the results of each trial 
still does not include enough of a treatment effect to reach statistical significance. With a 
small treatment effect, many more patients would be needed to demonstrate a statistically 
significant effect. The formal test of heterogeneity (appendix III) for the outcome of these 
three trials yields a Q-value of 0.187, which with two degrees of freedom ( df=2), leads to 
a p-value of0.689. This would indicate that the included trials are statistically 
homogenous and are able to be combined. The pooled estimate of albumin using the 
standard difference in means of the UDCA group compared to the placebo group was 
-0.232 using a fixed effects model with a 95% CI (-0.553,0.088) and a non significant p-
value of 0.156 (table 3.1 0). 
Table 3.10 
Outcome Measurement- Albumin (g/L) 
RCT UDCA Placebo Model SMD Lower 
95%CI (n) (n) 
F2 53 52 - 0.307 -0.691 
F3 13 13 - 0.200 -0.971 
F4 10 10 0.113 -0.764 
Overall 76 75 Fixed -0.232 -0.553 
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Upper P-value 
95%CI 
0.078 0.118 
0.571 0.611 
0.990 0.800 
0.088 0.156 
Note: RCT =Randomized controlled trial; UDCA = Ursodeoxycholic acid; 
n =The total number of patients in the group; SMD =standardized mean 
difference 
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Study name Outcome Sample size Std diff in means and 95% Cl 
UDCAPiacebo 
Mitchell, 2001 Albumin (g/L) 13 13 
Lindor, 1997 Albumin (g/L) 53 52 
Stiehl, 1994 Albumin (g/L) 10 10 
76 75 
-2.00 -1.00 0.00 1.00 2.00 
Favours UDCA Favours Placebo 
Note: lllCA = Ursodeoxycholic Acid; 9'L = gram per liter; std cliff = standard difference 
Figure 3.5: A Forest Plot; Using Standardized Mean 
Difference and 95% Cl, Comparing Albumin (g/L) levels in 
PSC Patients Receiving UDCA or Placebo. 
57 
3.6.6 Bilirubin. 
Four of the six fully published trials listed the results for the liver function 
bilirubin to be analyzed in this meta-analysis (F2,F3,F4,F6). However, one trial (F6) 
normalized the laboratory values and was not suitable for pooling in this meta-analysis. 
Examining Figure 3.6, we can see that one of the trials (F4) yields a statistically 
significant difference for bilirubin levels in favor of the UDCA group. Although two 
trials (F2,F3) trend toward a difference in bilirubin levels in favor of the UDCA group, 
the results do not reach statistical significance. The formal test of heterogeneity 
(appendix III) for the outcome of these three trials yields a Q-value of3.696, which with 
two degrees offreedom (df=2), leads to a p-value 0.158. This would indicate the 
included trials are statistically homogeneous and are able to be combined. The pooled 
estimate of bilirubin using the SMD ofthe UDCA group compared to the placebo group 
was -0.4 72 using a fixed effects model with a 95% CI ( -0.798, -0.14 7) and a statistically 
significant p-value of 0.004 (table 3.11 ). 
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Table 3.11 
Outcome Measurement- Bilirubin (umoljL) 
RCT UDCA Placebo Model SMD Lower Upper P-value 
(n) (n) 95% 95% 
Cl Cl 
F2 53 52 - 0.367 -0.752 0.019 0.063 
F3 13 13 -0.329 -1.103 0.445 0.404 
F4 10 10 - 1.372 -2.346 -0.398 0.006 
Overall 76 75 Fixed -0.472 -0.798 -0.147 0.004 
Note: RCT = Randomized controlled trial; UDCA = Ursodeoxycholic acid; 
n = Total number of patients in the group; SMD = standardized mean 
difference 
Study name Outcome Sample size Std diff in means and 95% Cl 
UDCAPiacebo 
Mitchell, 2001Bilirubin (umoVL) 13 13 
Lindor, 1997 Bilirubin (umoVL) 53 52 
Stiehl, 1994 Bilirubin (umoVL) 10 10 
76 75 + 
-4.00 -2.00 0.00 2.00 4.00 
FaWliS lttA FaWllS Placebo 
Note: UDCA= Ursodeoxycholic fcid; umoi/L = niao rrole per liter; std diff = slaldard difference 
Figure 3.6: A Forest Plot; Using Standardized Mean 
Difference and 95% Cl, Comparing Bilirubin (umoi/L) 
levels in PSC Patients Receiving U DCA or Placebo. 
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3.6.7 AST. 
Three of the six fully published trials listed the results for the liver enzyme AST 
to be analyzed in this meta-analysis (F2,F3,F6); however, one trial (F6) used normalized 
laboratory values for their analysis and was therefore not suitable for pooling in this 
meta-analysis. Examining figure 3.7, we can see that the trials show a treatment effect 
favoring UDCA. The formal test of heterogeneity (appendix Ill) for the outcome of these 
two trials yields a Q-value of0.750, which with one degree of freedom (df= l), yields a p-
value of 0.386. This would indicate that the included trials are statistically homogenous 
and are able to be combined. The pooled estimate of AST using the SMD of the UDCA 
group compared to the placebo group was -0.868 using a fixed effects model with a 95% 
CI (-1.227, -0.509) and a statistically significant p-value ofO.OOO (table 3.12). 
Table 3.12 
Outcome Measurement AST (U/L) 
RCT UDCA Placebo Model 
(n) (n) 
F2 53 52 
F3 13 13 
SMD Lower 
95% Cl 
Upper 
95%CI 
-0.792 -1.190 -0.395 
-1.201 -2.036 -0.366 
61 
P-value 
0.000 
0.005 
Overall 66 65 Fixed -0.868 -1.227 -0.509 0.000 
Note: AST =Aspartate aminotransferase; RCT = Randomized controlled 
trial; UDCA = Ursodeoxycholic acid; n= The total number of patients in 
the group; SMD = Standardized mean difference. 
Study name Outcome Sample size Std diff in means 
and95%CI 
UDCAPiacebo 
Mitchell, 2001 AST (U/L) 13 13 
Lindor, 1997 AST (U/L) 53 52 I 
66 65 + 
-4.00 -2.00 0.00 2.00 4.00 
fa\WS lJX'A fa\WS Placebo 
Note: UDCA= lksodeoxycholic ldd; lVl =units per liter; std diff = slaldcrd difference 
Figure 3. 7: A Forest Plot; Using Standardized Mean 
Difference and 95% Cl, Comparing AST (U/L) levels in PSC 
Patients Receiving UDCA or Placebo. 
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3.6.8 ALP. 
Five out of the six fully published trials listed the results for the liver enzyme 
ALP to be analyzed in this meta-analysis (Fl ,F2,F3,F4,F6); however, one trial (F6) used 
normalized laboratory values for their analysis and was therefore not suitable for pooling 
in this meta-analysis. Examining figure 3.8, we can see that two ofthe four trials (Fl ,F4) 
show a treatment effect favoring UDCA. The other two trials (F2,F3) show a trend 
towards favoring UDCA; however, do not reach statistical significance. This would 
imply at least some degree of heterogeneity between the groups. In fact, the formal test 
of heterogeneity (appendix III) for the outcome of these four trials yields a Q-value of 
25.192, which with three degrees offreedom (df=3), yields a p-value ofO.OOO indicating 
heterogeneity amongst the trials. 
The pooled estimate of ALP using the SMD of the UDCA group compared to the 
placebo group was -0.822 using a fixed effects model with a 95% CI (-1.153, -0.491) and 
a statistically significant p-value ofO.OOO (table 3.13). 
The trials were examined more carefully to try and explain the potential 
heterogeneity. One potential cause of heterogeneity for this outcome might be the wide 
range of UDCA (750mg to 20mg!kg/day) used in each study. However, looking at figure 
3.8, we can see that all treatment effects show a positive effect with variation in the size 
of that treatment effect favoring UDCA. This type ofheterogeneity is called quantitative 
heterogeneity and is acceptable for analysis. 
The non-significant x2 test for heterogeneity was interpreted with caution for the 
outcome measure ALP (U/L). It has been reported that the statistical test for 
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heterogeneity should be interpreted with caution when used in a meta-analysis that has a 
small number of trials as it may over estimate the overall heterogeneity ofthe trials 
(Spector & Thompson, 1991). 
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Table 3.13 
Outcome Measurement- ALP (U/L) 
RCT UDCA Placebo Model SMD Lower Upper P-value 
(n) (n) 95% Cl 95% Cl 
F1 6 8 -2.441 -3.832 -1.049 0.001 
F2 53 52 -0.536 -0.926 -0.147 0.007 
F3 13 13 -0.624 -1.411 0.163 0.120 
F4 10 10 -4.175 -5.738 -2.612 0.000 
Overall 82 83 Fixed -0.822 -1.153 -0.491 0.000 
Note: ALP= Alkaline phosphatase; RCT =Randomized controlled trial; 
UDCA = Ursodeoxycholic acid; n= The total number of patients in the 
group; SMD = Standardized mean difference. 
Study name Outcome Sample size 
UDCAPiacebo 
Mitchell, 2001ALP (U/L) 13 13 
Lindor, 1997 ALP (U/L) 53 52 
Stiehl, 1994 ALP (U/L) 10 10 
Beuers, 1992ALP (U/L) 6 8 
82 83 
Std diff in means 
and95% Cl 
-6.00 -3.00 0.00 3.00 6.00 
FavOU"S lDCA FavOU"S Placebo 
Note: UDCA= Ursodeoxycholic fcid; LVL =units per liter; std dill= standard difference 
Figure 3.8: A Forest Plot; Using Standardized Mean 
Difference and 95% Cl, Comparing ALP (U/L) levels in PSC 
Patients Receiving UDCA or Placebo. 
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3.7 Sensitivity Analysis- Publications Bias: 
Several outcomes have been analyzed in this meta-analysis. These outcomes 
included surrogate markers such as liver enzymes, liver function and histology and hard 
endpoints such as overall mortality and need for a liver transplant. Although we 
measured the overall mortality rates in this meta-analysis, the results were not statistically 
significant. This may have been because a difference in mortality does not exist between 
the UDCA and placebo groups or because the meta-analysis was underpowered to detect 
a statistically significant difference. A meta-analysis seeks to pool similar studies in order 
to identify a more accurate treatment effect. In the search for studies, there is always a 
possibility that non-significant trials have been carried out but remain unpublished. An 
extensive literature search should help to minimize this problem, commonly referred to as 
publication bias. 
Funnel plots can be used to look for evidence of publication bias. These are 
graphical representations comparing each trials effect size against a measure of its size 
such as sample size, standard deviation or standard error (Tonellli, Hackam, & Garg, 
2009). Trials with larger sample sizes should better approximate the true treatment 
effect, whereas small studies have more variation in their estimates of effect size as 
random variation plays a larger role (Tonellli, Hackam, & Garg, 2009). If a funnel plot is 
asymmetric towards small positive studies, there is a higher probability that small 
unpublished negative studies exist which may change the overall effect size ofUDCA. 
Funnel plots were performed on the outcomes in this meta-analysis that achieved 
statistical significance. Figure 3.9 demonstrates a funnel plot for the outcome of 
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bilirubin. The plot demonstrates that the included trials are symmetrical within the funnel 
plot; however, a smaller positive trial is present which is seen as being skewed towards 
the bottom left of the plot. In this particular case, there are only three studies used for 
analysis and therefore it is difficult to interpret the results of publication bias with any 
certainty. 
The outcome measurement ALP was also statistically significant in favor of a 
treatment effect for UDCA. Figure 3.1 0, a funnel plot looking for publication bias shows 
that two smaller studies are skewed to the bottom left of the funnel plot making it 
possible that small negative unpublished trials have been missed. There are only four 
studies used for this analysis, three of which contain very few patients and therefore it is 
difficult to interpret the results of publication bias with any certainty. 
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Figure 3.9: Funnel Plot of Standard Error by 
Standardized Mean Difference, for the Outcome 
Bilirubin (umol/L) in PSC Patients Receiving UDCA or 
Placebo. 
Figure 3.10: Funnel Plot of Standard Error by 
Standardized Mean Difference, for the Outcome ALP 
(U /L) in PSC Patients Receiving UDCA or Placebo. 
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Chapter 4 
Discussion 
This chapter provides an interpretation for the results of this meta-analysis 
including an assessment of the usefulness of the Jadad scoring system to determine a 
study's quality. A discussion of the use of surrogate markers in clinical research will be 
performed. This chapter will discuss the statistical methods used in meta-analysis with a 
focus on the use of MD and SMD to measure an outcomes effect size. Literature that was 
not included in this study but may have been useful and data that was missing from 
included studies in this meta-analysis will be reviewed. 
4.1 Quality of Studies- The Jadad Scoring System 
The Jadad scoring system (appendix I) was used to assess each trials quality. This 
method relies on explicit detail in the methodology section of each publication. This 
scoring system has some inherent advantages. It is convenient and easy to use as the 
system only incorporates five questions. An article can be assessed for quality usually in 
less than ten minutes. However, the Jadad five point scoring system is not without 
critique. An over simplified scoring system may give the impression that a score of four 
to five translates into a strong RCT. Generally speaking this may be true, however key 
methodology may still be lacking. There are no points awarded for power calculations to 
determine sample size or for describing how the withdrawals and dropouts are treated. 
Despite these shortcomings, the Jadad system is an accepted standard for quality scoring 
ofRCTs and is widely used. 
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Quality scoring systems, although helpful, may underestimate the overall quality 
of an RCT. Due to publication restrictions and limited space in some journals, the 
authors may be limited in the amount of detail they can include regarding trial design and 
analysis. Therefore, some trials may be penalized simply because they could not provide 
the necessary details to obtain a high quality score. 
4.2 Interpretation of Meta-Analysis 
PSC is a devastating disease affecting young people. It is often fatal without an 
eventual liver transplantation. Prior to liver transplant, patients are at higher risk for liver 
decompensation and an increased risk of malignancy. It is not surprising that there has 
been a lot of interest in pursuing medical treatments that might halt the progression of the 
disease and delay the time to death or the time to transplant. 
This meta-analysis set out to answer the question: 
"Does UDCA prolong survival in patients with PSC?" 
When research questions are initially formulated, it is very important to be as specific as 
possible in order to accurately answer the research question being asked. 
Immediate concerns about the above question may be: 
1. Prolong survival: By how much? What is clinically relevant for a delay in time 
to death? Some may suggest that any statistically significant difference between treatment 
groups may be relevant with an outcome such as mortality. 
2. Patients with PSC: An argument can be made that using this group as a whole 
is too broad. All patients with PSC are likely not equal. UDCA may have a different 
outcome on the disease depending on the patients' disease stage or the severity ofliver 
function at the time of treatment. Patients may respond differently if they are 
symptomatic at the time of diagnosis or if they have a more indolent course. 
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However, in this situation, PSC is such a rare condition that restricting the 
research question any further would eliminate the ability to identify pertinent trials. It was 
felt that a more appropriate plan would be to keep the question broad to seek all the 
available literature on this topic. In this way the results may be more generalizable to a 
wider group of patients. This would also increase the likelihood of being able to answer a 
research question on this topic. 
This question turned out to be more difficult to answer than expected. PSC is a 
rare disease and many of the trials that have been published have very small numbers and 
are underpowered to answer the above question. Whenever a rare disease is studied, 
there are also fewer studies available in the literature given the small numbers of patients 
available. There are also potential differences between trials in terms of methodology. 
There were differences in the RCT's used for this meta-analysis. The six trials 
differed in patient recruitment. Three of the trials had under thirty patients (Fl ,F3,F4); 
whereas three trials recruited over one hundred patients each (F2,F5,F6). It is obvious 
that the results of this meta-analysis would be weighted towards the larger trials. 
However, looking at the point estimate of effect for each trial, except for F6, we can see 
that although the CI's are large, the point estimate for each trial favors UDCA. Even 
though F6 showed an effect in favor of placebo, the effect was very small and not 
statistically significant. The 95% CI ' s for all six trials overlap. This would indicate that 
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for our primary outcome, although the trials are not weighted equally, they would appear 
at first glance to be fairly homogenous. 
The RCTs used all cause mortality as an outcome measurement; this could be 
criticized as being too broad; however, in this particular disease the patients are young 
and other than IBD, they do not have many co-morbidities. Indeed, when the results are 
looked at more carefully, all deaths apart from one patient can be directly attributed to 
PSC and its complications. 
Although the initial results for this meta-analysis could not detect a survival 
benefit for patients with PSC taking UDCA, perhaps a subgroup of patients taking high 
dose (> 15mg!kg/day) UDCA may experience a greater treatment benefit resulting in a 
prolonged survival. Larger doses of UDCA might be needed to provide sufficient 
enrichment of the bile acid pool in cholestasis and may enhance the irnmunomodulatory 
effects ofUDCA (Beuers, et al. , 2009). Three trials (F3,F5,F6) measuring mortality as an 
outcome used high dose UDCA and two trials (Fl ,F2) used low/standard dosing of 
UDCA. There was no treatment benefit in either subgroup for the outcome overall 
mortality. In fact, the one trial (F6) showing a higher mortality in the UDCA group, 
although not statistically significant, used high dose(> 15mg!kg/day) UDCA. Given the 
very small number of deaths observed, many more patients would need to be recruited to 
answer the question of survival benefit with UDCA. 
Three out of the four trials (F3,F5,F6) listing liver transplant as an outcome 
measurement used high dose (> 15mg!kg/day) UDCA. Although the results were not 
statistically significant, three of the four trials (F2,F3,F6) display a trend toward an 
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increased need for liver transplant in the UDCA group. The numbers of patients requiring 
liver transplant are too small to make any meaningful conclusion for this outcome 
measurement, however, it is interesting that three of the four trials suggest UDCA may 
increase a patients need for liver transplantation. Using high dose UDCA for this 
outcome measurement doesn't appear to add any treatment benefit. Examining these 
trials more carefully, it becomes apparent that patients were older than the mean age of 
diagnosis for PSC in all four trials (F2,F3,F5,F6) measuring this outcome. In addition, 
more than 50% of patients in two ofthese trials (F2,F3) had advanced histological 
staging. One trial (F5) did not include histological staging as an outcome measure. 
Certainly older age and advanced histological staging may signify a poorer prognosis in 
PSC. Theses reasons may have contributed to the increased need for liver transplant in 
these studies irrespective of the treatment group and may be contributing factors for the 
apparent lack of efficacy of UDCA for this outcome measurement. 
We suspected that our primary outcome would be difficult to demonstrate with 
the available literature. A priori, we decided to examine a number of surrogate outcome 
measurements to help answer our primary research question. 
It has been shown that before patients die from liver disease or require a 
transplant, they deteriorate in terms ofliver function (albumin, bilirubin), liver 
biochemistries {AST, ALP) and histology. Many of the trials measured these variables 
before and after treatment with UDCA, as surrogate markers for improvement in the 
underlying liver disease. We therefore decided to use these surrogate markers as 
outcome measurements in our meta-analysis. Our hypothesis was that if we could detect 
a statistically significant improvement in these outcome measurements following 
treatment with UDCA, then we could infer a treatment benefit in favor ofUDCA. The 
following section will discuss the use of surrogate markers in clinical research. 
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A change in liver histology was recorded for four of the six trials. Our outcome 
measurement was worsening of liver histology at the end of each study. The meta-
analysis shows no significant difference between UDCA and placebo groups. The largest 
study measuring this outcome (F2) actually recorded a trend toward worsening of liver 
histology for the UDCA group, although the results were not statistically significant. The 
heterogeneity of these trials is likely explained on the basis of sampling error in the 
histology for PSC. As previously mentioned, this is a patchy disease and the same 
patient may demonstrate completely different histological stages of disease depending on 
the area of the liver biopsied (Cullen & Chapman, 2005). Any study that uses histology 
alone as an end point for this disease should be interpreted with caution. 
In order to determine when patients with PSC have advanced disease, there are 
several validated scoring systems that are based on clinical and biochemical parameters 
which can be used. The mayo-risk score for liver disease (Kim W. , et al. , 2000) and the 
model for end stage liver disease (MELD) score (Kamath, et al. , 200 I) are two of the 
most widely used scoring systems to predict survival. The MELD scores are helpful for 
prioritizing patients for transplant and are often used as the basis for listing patients for 
liver transplant. Wiesner, et al ; demonstrated the use of the MELD score in liver 
transplant allocation based on three month survival rates for 3437 patients awaiting liver 
transplant. Patients having a MELD score less than nine experienced a three-month 
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survival of 98%, whereas a score of forty experienced a three month survival of only 30% 
(Wiesner, et al., 2003). 
The Mayo-risk score for PSC is as follows: 
R = 0.03(age[y]) + 0.54logc (bilirubin [mg/dl]) + 0.54lo~(AST [U/L]) + 1.24(variceal 
bleeding [0/1]) - 0.84(albumin[g/dL]). 
R= risk score 
Variceal bleeding: 0= no prior bleed, 1 = prior bleed 
Probability of survival at timet years is calculated as S(t)= S0(t)exp(R-I.OO) 
Survival function coefficient [S0(t)] 
1 year = 0.963, 2 years = 0.919, 3 years = 0.873, 4 years = 0.833 
The MELD score is as follows: 
MELD = 3.8[Ln serum bilirubin (mg/dL)] + 11.2[Ln INR] + 9.6[Ln serum creatinine 
(mg/dL)] + 6.4 
These validated scoring systems use surrogate markers to try and predict hard 
outcomes such as mortality and need for liver transplant in patients with PSC. It is 
therefore appropriate that we chose bilirubin, AST and albumin as surrogate outcome 
measurements for this meta-analysis. Although not included in the above scoring 
systems, we have also chosen ALP as an outcome measurement because PSC is a 
cholestatic disease and ALP is the most affected liver enzyme in cholestasis. This liver 
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enzyme may not have been included in the above scoring system as the value can be 
influenced by extra-hepatic biliary obstruction that can occur in PSC, through benign and 
malignant strictures, and may not be reflective of the severity for the underlying liver 
disease. 
The analysis of albumin in this meta-analysis identifies a trend towards 
improvement in the UDCA group in patients with PSC; however, statistical significance 
was not achieved. The trials were determined to be homogeneous for this outcome using 
the x2 test for homogeneity. It is possible that if more patients were recruited for these 
studies then a statistically significant difference may have been observed given that the 
treatment effect for most trials was in favor of the UDCA group. 
The outcomes for bilirubin, AST and ALP all achieved statistical significance in 
favor of the UDCA group. 
The surrogate markers for our primary outcome showed either a statistically 
significant benefit in favor of UDCA or a trend towards significance. A larger 
recruitment of patients or further RCTs may have determined statistical significance for 
these non-significant outcomes. Whether these surrogate outcomes can reliably predict 
survival or time to transplant needs to be addressed. 
4.3 The Use of Surrogate Markers in Clinical Research 
It is becoming more common for RCTs to use surrogate markers for measuring 
the effect of medical therapy on disease. Ideally outcome measures are clinically firm 
endpoints such as death or time to an event (eg. transplant, dialysis). Unfortunately, it has 
become increasingly more difficult to measure treatment efficacy with these "hard" 
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outcome measurements, especially when a disease is rare (eg. PSC) or the time to an 
event (death, transplant) is long. In this situation "hard" outcomes are challenging to use 
because of the large sample size needed and the length ofthe trial that would need to be 
conducted. Investigators are always looking for ways to answer their research questions 
more efficiently and effectively. If it was possible to use a "surrogate" outcome that was 
easily measured and occurred at an earlier time point than the "hard" outcome, the study 
might take a shorter time to conduct and might need fewer patients to be recruited. 
There has been a lot of research performed using biomarkers as surrogates for 
hard outcomes. Ideally there should be a strong independent and consistent association 
between the surrogate end point and the clinical end point (Bucher, Guyatt, Cook, 
Holbrook, & McAlister, 1999). The use of proteinuria as a surrogate marker for time to 
dialysis is one example. It has been well validated that continued worsening proteinuria 
serves as an indicator of impending renal failure and the requirement of dialysis. There 
should also be RCT evidence that improvement in the surrogate end point is consistently 
associated with improvement in the target outcome (Bucher, Guyatt, Cook, Holbrook, & 
McAlister, 1999). Using the same example of proteinuria as a surrogate marker for renal 
failure, there is evidence that both angiotensin converting enzyme (ACE)-inhibitors and 
angiotensin receptor blockers (ARBs) are effective at lowering proteinuria and delaying 
progression to renal failure (Rigatto & Barrett, 2009). 
It would appear that using surrogate markers instead of"hard" outcomes for 
clinical trials is a useful alternative when investigating a disease that is rare or when the 
outcome of interest takes a long time to develop. Unfortunately, there are many pitfalls 
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that the researcher needs to be aware of before choosing a surrogate marker. Although 
surrogate markers may be associated with the disease of interest, this does not imply that 
they can be used in place of clinically relevant outcomes for a disease. For instance, low 
levels of high-density lipoprotein (HDL) are associated with worsening atherosclerotic 
disease. However, in a trial using the drug torcetrapib, HDL levels were increased but 
this did not translate into a change in progression of coronary artery disease (Rigatto & 
Barrett, 2009). 
Another consideration when using surrogate markers instead of "hard" outcomes 
is the fact that validation of a surrogate marker for one intervention does not imply that 
the same surrogate is valid for another intervention. For instance, when statins are 
investigated, low-density lipoprotein (LOL) cholesterol levels serve as a useful surrogate 
for cardiovascular disease. However, when a medication called sevelamer was studied, 
decreased levels of LDL did not translate into lower levels of cardiovascular disease 
(Rigatto & Barrett, 2009). 
It is also possible that not all treatment effects can be accounted for by a single 
biomarker (Atkinson, eta!., 2001 ). Often multiple markers are needed in combination to 
account for treatment effects and outcome measurements. An example of this would be 
the MELD score that uses a combination of markers (bilirubin, INR, creatinine) to 
approximate liver disease severity in order to help allocate liver transplants. This meta-
analysis demonstrates a non-statistically significant trend in favor of an increased need 
for liver transplant in the UDCA group. The trials did not mention measuring INR or 
creatinine. Either these were measured and not reported or an alternative model was used 
to determine allocation for liver transplant. The mayo risk score has been validated to 
determine survival for patients with PSC, perhaps this scoring system was used to 
determine the need for liver transplant in each trial. 
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Another consideration that must be observed when using surrogate markers is the 
potential for treatments being studied to cause harmful effects on the outcomes that were 
not measured. The dopaminergic agent ibopamine had been shown to positively 
influence such surrogate outcomes for heart failure as ejection fraction and heart rate 
variability; however, an RCT then demonstrated that the drug actually increased mortality 
in patients with heart failure (Bucher, Guyatt, Cook, Holbrook, & McAlister, 1999). 
In hepatology, a number of surrogate markers used in research and clinical 
practice have not been properly validated (Gluud, Brok, Gong, & Koretz, 2007). The 
authors suggest that there are two steps necessary to validate a surrogate marker. The first 
step is to demonstrate a correlation between the surrogate and the clinical outcome. For 
instance, there is a strong correlation between serum bilirubin and mortality, which has 
been validated as one of the strongest surrogate markers in Mayo models (Gluud, Brok, 
Gong, & Koretz, 2007). The second step is to prove that the interventions effect on the 
surrogate marker predicts the interventions effect on the hard outcome. The authors 
suggest that in the case of PBC, despite UDCA showing an improvement in bilirubin 
levels, this does not translate into an improvement in mortality (Gluud, Brok, Gong, & 
Koretz, 2007). 
Our current meta-analysis attempted to answer the question of whether UDCA 
prolongs survival in patients with PSC. Surrogate markers of liver histology, liver 
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biochemistries and liver function were used for clinical outcomes such as mortality and 
time to transplant. PSC is a patchy disease and therefore it may not be appropriate to use 
worsening liver histology as a surrogate marker. Liver biopsies have the potential for 
sampling error and may not accurately reflect the true stage of the disease. 
Critically appraising these surrogate markers with the information stated above 
would suggest that no one individual marker would be sufficient to predict mortality and 
time to transplant. However, looking at a combination of markers may be more 
appropriate. The mayo risk score for PSC outlined above, uses surrogate markers 
(bilirubin, albumin, AST) in addition to the static markers age and history of variceal 
bleeding to predict survival in patients with PSC. A similar model is used for PBC. One 
study showed that this model for PSC was validated in 124 patients. The results showed 
good correlation between the estimated survival using this model and actual survival 
(Kim W. , et al., 2000). It seems reasonable that the trials evaluating UDCA used AST, 
bilirubin and albumin as surrogate outcomes for survival in patients with PSC. ALP 
levels may be influenced by external biliary strictures and would therefore not always be 
associated with liver dysfunction. There is no conclusive evidence that ALP alone may 
be used as a reliable surrogate marker when evaluating treatments and predicting disease 
outcome in patients with PSC. 
Using Gluud's review on surrogate markers, the first step in surrogate outcome 
validation would be fulfilled in that there is a correlation between the surrogate marker 
and the clinical outcome, as demonstrated by the Mayo score. However, as seen in this 
current meta-analysis, the second step of surrogate marker validation was not fulfilled. 
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UDCA's effect on the surrogate markers did not accurately predict UDCA' s effect on the 
hard outcomes. Perhaps there were too few hard outcomes of mortality or need for 
transplantation to detect a statistically significant difference in treatment groups. 
Alternatively, treatment may need to occur much earlier in the course of the disease to 
modify hard outcomes. 
4.4 The Use of Mean Difference and Standardized Mean Difference in Meta 
Analysis 
Meta analyses have traditionally used binary outcomes to create pooled effect 
sizes and CI's. The results are usually reported as pooled odds ratios with 95% CI's. This 
meta-analysis analyzed data using both binary outcomes (mortality, worsening of liver 
histology and requirement for liver transplant) and continuous data (liver biochemistries 
and liver function). 
When continuous data are used for outcome measurements, either mean 
differences (MD) or SMD's can be calculated for each trial and these results can be 
combined to produce a pooled MD or SMD with 95%CI. However, this type of meta-
analysis appears to be more complicated in its statistical pooling of the included trials 
(Gotzsche, Hrobjartsson, Marie, & Tendal, 2007). According to the Cochrane 
collaboration, there are several ways to calculate the pooled mean difference using 
continuous data. The simplest way to pool continuous data is to record the sample size, 
mean and standard deviation in each group at the beginning and end of the study. The 
mean difference and standard error can then be calculated. Each trial can be assigned a 
weight and the inverse variance method of meta-analysis can be used to create a pooled 
--------------------------------------------------------
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mean difference along with its CI. In order to accurately combine the data amongst 
different trials, it is important to ensure that the continuous outcomes from different 
studies use the same units of measurement. When units of measurement cannot be 
converted to the same unit, SMD's can be used instead of the MD. The SMD is the 
difference in means divided by the standard deviation (SD). The SD is the pooled SD of 
patient outcomes in the whole trial. 
There are potential pitfalls to using the SMD in meta-analysis. It is important to 
ensure that the measurement scales used in each trial are measuring the same outcome. 
Problems can also occur when inclusion criteria differ between studies, as tighter 
inclusion criteria may create populations that are more similar resulting in smaller SD. If 
two or more studies show an equal treatment effect, the SMD might be different amongst 
these equal studies as the SO might be smaller in those studies using tighter inclusion 
criteria (Alderson & Green, 2002). Another potential problem with using MD and SMD 
in meta-analyses is the interpretation of skewed data. Outliers have the ability to skew 
the mean, ultimately leading to an effect size that may not be truly representative of the 
data (Alderson & Green, 2002). 
Gotzsche, et al; looked at data extraction errors in meta-analyses that use SMD 
and found many errors occurred during the data extraction process. Errors that this group 
found included the extraction of standard error (SE) instead of SD. The authors 
concluded that this would inflate the overall effect estimates. 
Data abstractors need to know the direction of the effect size in order for the 
analysis of continuous data to be accurate. This can become difficult in some settings 
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where a high score can signify a negative outcome such as certain depression scores 
(Gotzsche, Hrobjartsson, Marie, & Tendal, 2007). Of the 21 meta-analyses reviewed by 
Gotzshe, et al; there were errors affecting the outcome of the results in 63% of the 
studies. One meta-analysis was subsequently retracted and in two studies, a significant 
difference in results disappeared or appeared. The authors concluded that meta-analyses 
using MD or SMD for reporting pooled effect sizes should be interpreted with caution. 
Indeed, the statistics can be more challenging for continuous measurements than for 
binary outcomes in meta-analysis. However, if more than one person carries out data 
abstraction and differences are discussed and consensus is reached, one would suspect the 
meta-analysis would be less likely to have significant error. 
It is difficult to interpret the results of meta-analysis using SMD as the effect sizes 
and CI's are reported in standardized values. As each trial has been weighted differently, 
there is no set SD that can be used to convert the values back into clinically meaningful 
MD. Perhaps this type of analysis is better served as a qualitative measure of strength for 
the treatment effect and can serve as an indicator for treatment effect direction. 
4.5 Potential Pitfalls With The Test For Heterogeneity 
A meta-analysis cannot be performed until the investigator determines if the 
studies being examined are similar enough to combine the results. It is the statistical 
pooling of results that forms the meta-analysis. However, as previously outlined, there 
are several steps in between that add to the overall quality of a meta-analysis. One 
essential part of the process is determining whether the results of each study are similar 
enough to be combined. This is termed "homogeneity" and should be accomplished first 
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qualitatively by observing the trials similarities (eg. study populations, treatments 
received, trial duration) and then quantitatively by looking at effect directions and CI for 
each outcome. Once the trials appear homogenous through the examination of each trial 
(qualitative analysis), a statistical test for heterogeneity can be performed (quantitative 
analysis). If the p-value for the X2 test of heterogeneity is >0.1 , the trials are felt to be 
similar enough to be combined. 
Unfortunately, the overall power for the x2 test of heterogeneity can be low under a few 
different circumstances that may apply to this current meta-analysis. If the overall 
amount of data that each trial provides is low or when the meta-analysis is heavily 
weighted by studies with many more included patients than the other studies; such as the 
RCTs (F2,F5,F6), the test of heterogeneity may have low power and should be 
interpreted with caution (Hardy & Thompson, 1998). 
4.6 The Fixed and Random Effects Models in Meta-Analysis 
The fixed effect and random effect methods are two statistical models that can be 
used to combine data in a meta-analysis. The fixed effects model assumes that the same 
underlying treatment effect is observed between studies. In this situation there is within 
study variance to consider but between study variance is felt to be due to random error 
alone. If the test of heterogeneity is non significant (meaning the outcomes of the studies 
are statistically similar), then using a fixed effects model for combining studies will give 
a more precise estimate of treatment effect (Spector & Thompson, 1991 ). However, if 
studies are not felt to be homogeneous then a random effects model can be used. A 
random effects model takes into account both between study variance and the within 
study variance (Spector & Thompson, 1991 ). 
One solution to determining the ability of the test of heterogeneity to detect variability 
between trials is to first perform an analysis with the fixed effects model. If the test of 
heterogeneity is significant then perform a random effects analysis. If the fixed effects 
and random effects model provide the same results then the individual studies are more 
likely to be homogenous and there is adequate power in the x2 test for heterogeneity 
(Alderson & Green, 2002). 
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This meta-analysis reported fixed effects results when the combined analysis was 
homogenous. When there was quantitative heterogeneity present then a random effects 
model was viewed and compared to the results of the fixed effects model ; however, 
ultimately a fixed effects model was chosen in this situation because the small number of 
trials included in this meta-analysis would limit the ability of a random effects model to 
detect between trial variation (Borenstein, Hedges, & Rothstein, 2007). 
4.7 Publication Bias 
Funnel plots were used to graphically demonstrate potential publication bias in 
this meta-analysis. There has been considerable research in developing statistical methods 
to help quantify publication bias as well. One method called the failsafe N approach is 
based on Rosenthal's theory called the "file drawer" theory, meaning that there may be 
several small non-published studies that may not be accounted for as they remain in 
someone's file drawer (Rosenthal, 1979). A formula was created that determines how 
many unpublished studies would be required to make the effect no longer statistically 
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significant. The problems with this method of assessing publication bias is that the 
formula assumes that the mean effect size in the missing studies is nil, when in fact the 
effect size may be positive or negative, thus altering the number of missing studies 
needed to render the effect size non significant. The Rosenthal method is also based on 
combining p-values across studies; however, meta-analysis computes p-values for the 
combined effect, thus decreasing the value of the failsafe N method for detecting 
publication bias in meta-analysis (Borenstein M. , 2005). 
Egger's regression is another method for statistically assessing publication bias. 
This method employs linear regression to quantify bias captured by the funnel plot. The 
standard normal deviate is regressed on precision (inverse ofthe standard error). The size 
ofthe treatment effect is captured by the slope of the regression line and bias is captured 
by the intercept (Borenstein, Hedges, Higgins, & Rothstein, 2005). 
These statistical methods for assessing publication bias should only be used when 
there is a range of studies with different volumes of patients (Borenstein M. , 2005). 
Although funnel plots can be used to graphically demonstrate publication bias for this 
meta-analysis, statistical methods to assess publication bias may be misleading. 
4.8 Literature That May Have Added To This Meta-Analysis 
The literature search identified one trial that may have been useful for this meta-
analysis (De Maria, Colantoni, Rosenbloom, & Van Thiel, 1996). This study was 
reviewed and data extracted by two independent abstractors. Unfortunately all the data 
needed for entry into the meta-analysis was not available for abstraction. The authors for 
this study were contacted but didn' t answer our request for more data. This section 
presents a summary of this trial outlining the potential relevance for our current meta-
analysis. 
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In 1996, DeMaria, et al; published an article titled "UDCA does not improve the 
clinical course ofPSC over a 2 year period" (De Maria, Colantoni, Rosenbloom, & Van 
Thiel, 1996). This was a RCT including 59 patients with PSC. There were three groups 
including 20 patients in the UDCA group (300mg/day), 20 patients in the placebo group 
and 19 patients in a third arm using colchicine. This study was conducted over 24 
months with regular three month follow up to assess disease status. At the end of the 
study period, it was determined that no group was different in regards to liver function or 
liver injury. The authors concluded that UDCA was no better than colchicine or placebo 
for PSC. In terms of combinability with our other studies, the average age in the UDCA 
group was 32 ( +/- 5.1) and 31.2 (+/- 5.0) in the placebo group. There were more males 
present with a ratio of 14/6. Approximately 45% of patients in the study had UC. The 
average histologic stage of disease at the beginning of the study was 2.2 (+/0.4) in the 
UDCA group and 2.3 (+/- 0.2) in the placebo group. 
The study participants were slightly younger and at an earlier stage of disease than 
some of the other studies used in this meta-analysis. There are also fewer patients with 
IBD (UC or crohn's) than the other studies included in this meta-analysis. Further 
heterogeneity may be explained by the dosage ofUDCA used in this study. Based on an 
average 70 kg male, the dosage used would be 4.2 mglkg/day, which was well below the 
dosing used in our current meta-analysis (1 0-30mg/kg/day). The Jadad scoring system 
would generate a quality score of three out of five. Points were lost for not describing 
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how blinding was carried out as well as determining whether all patients were accounted 
for at the end of the trial. Unfortunately pre and post values were not included for liver 
biochemistries and function. There was no data available for overall mortality. This 
study may not have added to our overall results as the study likely used an inadequate 
dose of UDCA to achieve a clinical difference in study endpoints. 
4.9 Incomplete Data From Studies Included In This Meta-Analysis 
Two trials (F5 and F6) were included in this study because mortality and 
requirement for liver transplant data were available, however, no interpretable data was 
available for the surrogate outcomes measured. The authors for the Olsson study (F5) 
were contacted but didn't answer our request for more data. This section presents a 
summary of these trials outlining their potential relevance for our current meta-analysis. 
In 2005, Olsson, et al ; published an article titled "High dose UDCA in PSC: A 5-
year multicenter RCT" (Olsson, et al. , 2005). This was an RCT including 2 19 patients 
with PSC. There were two groups including 110 patients in the UDCA group (17-
23mg/kg/day) and 109 patients in the placebo group. This study was conducted over five 
years with follow up at six-month intervals. At the end of the study period, it was 
determined that there was no statistically significant difference between groups in the 
primary outcome measurement of death or liver transplant. There was a trend for 
significance in liver enzymes and function. The authors concluded that there was no 
benefit to using high dose UDCA in patients with PSC. In terms of assessing qualitative 
homogeneity with our other studies, the average age in the UDCA group was 43.6 (+/-
12. 7) and 43.1 (+/- 11.2) in the placebo group. This study included 70% males and 85% 
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of patients had IBD. There was no histology data for this study. These patient 
characteristics were similar to the patients included in the other studies for this meta-
analysis and would therefore appear appropriate to be used for analysis. The Jadad 
scoring system generated a quality score of four out of five. One point was lost because 
details of the randomization process were not explained. Although pre UDCA/placebo 
values were given for liver biochemistry and liver function, the post results were not 
explicit and were demonstrated in graph form only. This study's complete results would 
have been useful for our meta-analysis as there was good methodology used and patients 
appeared similar to the other studies used for this meta- analysis. This study's data on 
liver biochemistry and function would have helped to balance the other large study by 
Lindor, et al; 1997, that was included in the meta-analysis. A subgroup analysis for the 
surrogate outcomes may have been possible comparing high dose UDCA 
(> 15mg/kg/day) to regular dosing ( 1 0-15mglkg/day). This study did include mortality 
and liver transplant data that could be used for the meta-analysis. To date, this study is 
the largest one published with the longest follow up period comparing UDCA to placebo 
in patients with PSC. A complete meta-analysis has to be interpreted with caution if this 
trials data on liver enzymes and function have not been included in its results. Despite 
attempts at contacting the authors, no response was received. 
In 2009, Lindor, et al; published an article titled "High-Dose Ursodeoxycholic 
Acid for the Treatment of Primary Sclerosing Cholangitis" (Lindor, et al., 2009). This 
was an RCT including 150 patients with PSC. There were two groups including 76 
patients in the UDCA group (28-30mglkg/day) and 74 patients in the placebo group. 
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This study was designed to follow patients with PSC for five years; however, ended after 
six years of patient recruitment secondary to futility. At the end of the study period, it 
was determined that 39% ofthe patients in the UDCA group versus 26% of patients in 
the placebo group had reached one of the pre-established primary endpoints (table 3.5). 
After adjusting for baseline characteristics, the authors determined that the risk of death, 
liver transplant or minimal listing criteria was two times greater for the patients in the 
UDCA group. Although there was a trend for increased mortality and requirement for 
liver transplant in the UDCA group, these results did not reach statistical significance. At 
three years, there was a statistically significant difference between liver biochemistry and 
function favoring UDCA. The authors concluded that although long term, high dose 
UDCA improved serum liver enzymes and function, this did not translate into an 
improved survival for patients with PSC. Trial similarities were assessed with our other 
included studies. The average age in the UDCA group was 46.6 and 45.3 in the placebo 
group. This study included 57% males and 77% of patients with IBD. The dosage of 
UDCA used in this study was 28-30 mglkg!day, which is the highest dosage used of all 
included trials in this meta-analysis. This study's mean age was higher than the majority 
of our included trials and higher than the mean age of diagnosis for patients with PSC. 
This study included more females with PSC than the majority of our included trials and a 
higher percentage of females than what would be expected from the general population 
with PSC. These baseline characteristics would suggest that this trial showed a degree of 
heterogeneity compared to the other included trials in this meta-analysis and perhaps this 
trial may not be generalizable to a typical population with PSC. 
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Liver biopsies were taken before randomization and after five years in 31 patients. 
Six patients in the UDCA group and four patients in the placebo group developed 
cirrhosis. Unfortunately, the authors did not provide any further data on worsening of 
liver histological stage for both treatment groups. These results could not be used in our 
meta-analysis as they may underestimate the number of patients who developed 
histologic progression in liver disease as patients can develop worsening in histological 
stage without necessarily developing cirrhosis. 
Although there was information provided on pre/post UDCA and placebo values 
for liver biochemistry and liver function, the results were displayed in normalized values 
and were therefore not suitable for pooling with the other included RCTs. Interestingly, 
the results show that liver biochemistry and function improved in the placebo group from 
baseline. This observation would not be expected from the natural history of disease in 
PSC and was not observed in other trials using high dose UDCA. 
This study's data on liver histology and liver biochemistry/function would have 
helped to balance the other large study by Lindor; et al from 1997, that was included in 
this meta-analysis. A subgroup analysis may have been possible comparing high dose 
UDCA (> 15mglkg/day) to regular dosing (1 0-15mglkg/day). This study did include 
mortality and liver transplantation data that could be used for the meta-analysis. 
Interestingly, this study was the only one that showed a trend toward increased mortality 
for the UDCA group. The study authors suggested that UDCA may modulate apoptosis. 
Perhaps a higher dose ofUDCA prevented apoptosis of activated stellate cells, which 
continued to be active in fibrogenesis ultimately leading to deterioration in liver disease 
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(Linder, et al. , 2009). The authors also suggested that higher doses ofUDCA may cause 
unabsorbed medication to enter the colon and be modified into hepatotoxic bile acids. 
These theories may explain the results of this particular study, although the other studies 
using high dose UDCA (F3,F5) did not demonstrate similar findings. 
4.10 Ursodeoxycholic Acid in Primary Sclerosing Cholangitis: A Comparison of 
Two Meta-Analyses 
In 2009, Shi et al; published a meta-analysis titled "Ursodeoxycholic Acid in 
Primary Sclerosing Cholangitis: Meta-Analysis of Randomized Controlled Trials (Shi, 
Li, Zeng, Lin, & Xie, 2009). This was a meta-analysis that included eight studies. Six of 
the included studies (Beuers, et al. , 1992), (Stiehl, Walker, Stiehl, Rudolph, Hofmann, 
& Theilmann, 1994), (De Maria, Colantoni, Rosenbloom, & Van Thiel, 1996), (Linder, 
1997), (Mitchell, Bansi, Hunt, Von Bergmann, Fleming, & Chapman, 2001), and 
(Olsson, et al. , 2005), were fully published and two were in abstract form (Lo, et al., 
1992), (Bansi, Christie, Fleming, & Chapman, 1996). 
In comparison, our current meta-analysis included five of the eight trials used in 
the Shi, et al. , 2009 study and one RCT that was not included in the meta-analysis by Shi. 
The trials by (Beuers, et al. , 1992), (Stiehl, Walker, Stiehl, Rudolph, Hofmann, & 
Theilmann, 1994), (Linder, 1997), (Mitchell, Bansi, Hunt, Von Bergmann, Fleming, & 
Chapman, 200 I), (Olsson, et al. , 2005) were included in this current meta-analysis, 
however, the study by (De Maria, Colantoni, Rosenbloom, & Van Thiel, 1996) was 
excluded as there was no placebo group. We chose only placebo controlled trials for our 
meta-analysis in order to assess the true effect of Ursodeoxycholic acid. Combining 
placebo controlled trials and non-placebo controlled trials could lead to unwanted 
heterogeneity. 
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Our current meta-analysis decided a priori to pool published abstracts separately 
and include them in a sensitivity analysis if adequate data were available for abstraction. 
The abstract by Lo, et al., 1992 was reviewed in our current meta-analysis, however, 
there was insufficient information included in the abstract for analysis. The abstract by 
Bansi, et al. , 1996 was also reviewed and excluded from our current meta-analysis as it 
was felt to have been published later as a full RCT. This would have implications if 
patients included in the meta-analysis were recorded twice. 
Our current meta-analysis also included the latest RCT by Lindor, et al. , 2009, 
which was not available for the meta-analysis by Shi, et al. , 2009. The Lindor, et al. , 
2009 study was ofhigh methodological quality and included a large number of patients. 
A meta-analysis that does not include this RCT would have to be interpreted with 
caution. 
The primary and secondary outcomes were not clearly defined in the study by 
Shi, et al., however, they did include the outcomes assessed in our current meta-analysis. 
Forrest plots were not included for graphical demonstration of results in the study by Shi, 
et al. , however, OR and 95% CI along with p-values were shown. In our current study, 
statistical analysis was displayed using OR along with 95% CI for binomial outcomes 
and with SMD along with 95% CI for continuous outcome measurements. Forest plots 
were used for graphical demonstration of the results. 
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The meta-analysis by Shi, while it included more RCTS than our meta-analysis, must be 
interpreted with some caution. The trials included in a meta-analysis should be 
homogeneous in terms of design and the results which are available for analysis. 
Combining trials with differing designs and with limited data available for analysis may 
lead to spurious results. A failure to include the most up to date trials may lead to out of 
date conclusions. 
- ------ ------------------------------
Chapter 5 
Conclusion 
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This chapter is divided into two sections. The first part presents the educational 
lessons that have been observed during this research endeavor. The second part focuses 
on the particular conclusions that are relevant to this meta-analysis. 
At the time this study was initially conducted, there were few meta-analyses using 
continuous variables. Performing the meta-analysis using SMD and investigating the 
potential complications and challenges when such an analysis is performed was 
educational. 
Reported results using continuous variables need to be interpreted with caution 
given the difficulty in such a statistical analysis and the many possible errors encountered 
in combining such data. 
Statistical tests for heterogeneity are not the only way to assess homogeneity 
amongst trials and the test itself needs to be interpreted with caution especially when the 
trials combined have few patients. 
However, meta-analysis is still very useful in research. This type of study can help 
answer questions on medical management when there are several well-conducted trials 
with non-significant results, usually because each trial is underpowered. The results can 
be pooled to achieve an overall effect size for the outcome being observed in the hopes of 
achieving statistical significance. 
This meta-analysis would suggest that there are significant differences between 
the UDCA and placebo group for the surrogate outcomes bilirubin, ALP and AST. If 
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further data were available from the trials, we may have been able to calculate average 
Mayo risk scores for each trial and then pool these scores to get a better assessment of the 
usefulness of UDCA in PSC. Combining surrogate markers in this fashion (i.e. using a 
previously validated scoring system) may have been more appropriate to help answer our 
research question. 
Alternatively, if individual patient data were available, the results may have been 
combined for each outcome measurement to increase the strength of this study; as 
opposed to combining individual study results for each outcome. The acquisition of 
individual patient level data may have increased the ability to infer a treatment effect. 
However, when combining individual patient results across studies, continuous outcome 
measurements such as laboratory values would have to be standardized in each study to 
ensure the validity of combining the data. 
When all cause mortality was analyzed on its own and by the subgroup ofUDCA 
dosage, there was no significant difference between treatment groups. A conclusion 
cannot be made whether UDCA can prolong survival in patients with PSC. Perhaps with 
more patients a treatment effect may have been seen. PSC affects young people and has 
devastating complications including liver failure and malignancy. It will be important for 
research in this area to continue. Further study may need to be performed to accurately 
answer our current research question. Perhaps ifUDCA is used earlier in the course of 
the disease, more favorable outcomes may be observed. After the 2009 Lindor study, it is 
less likely that further research will be done using high dose UDCA in PSC. Three high 
dose UDCA trials (F3,F5,F6) have failed to demonstrate an improvement in overall 
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survival and time to transplant. Although the latest study (F6) may not appear to be 
generalizable to a typical population of patients with PSC, the study was well performed 
with good methodology. The study demonstrated worse outcomes in the UDCA group, 
although these results were not statistically significant. Future research may focus on 
alternative treatment strategies to slow the progression of disease in patients with PSC. 
After a careful review of the literature, it would appear that further research is 
needed to explore the role of surrogate markers for clinical outcomes in the field of 
hepatology. Although scoring systems such as the Mayo risk score have shown a 
correlation with clinical outcomes in PSC, this has not been confirmed in clinical trials. 
Perhaps, these clinical trials had too few outcomes to detect a statistically significant 
difference in clinical outcome measurements. The other possibility is that current 
surrogate markers being used in PSC such as liver biochemistry and function may not be 
effective for detecting hard clinical outcomes such as death and time to transplant. 
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Jadad Quality Score Calculation 
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Jadad Score Calculation 
1) Was the study described as randomized (this includes words such as randomly, 
random, and randomization)? 0/1 
2) Was the method used to generate the sequence of randomization described and 
appropriate (table of random numbers, computer-generated, etc)? 0/1 
3) Was the study described as double blind? 0/1 
4) Was the method of double blinding described and appropriate (identical placebo, 
active placebo, dummy, etc)? 0/1 
5) Was there a description of withdrawals and dropouts? 0/1 
6) Deduct one point if the method used to generate the sequence of randomization 
was described and it was inappropriate (patients were allocated alternately, or 
according to date of birth, hospital number, etc). 0/-1 
7) Deduct one point if the study was described as double blind but the method of 
blinding was inappropriate (e.g., comparison of tablet vs. injection with no double 
dummy). 0/-1 
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Appendix II 
Data Extraction Sheet 
Data Extraction Sheet for :Meta-Analvsis: 
Js UDCA Effective at Preventing Disease Progression 
in Patients with l,SC? 
Title: -------------------------------
Author(): _________________________________ __ 
Journal: -·-.. -·-·-- Abstract: ___ _ 
Name of Journal: _ _ _ 
Conference (If appli<:able): 
Country of Publkation: ------
Total# of Pts: ____ _ 
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Tx group: _ __ ...zpts placebo grp: __ __.p. ts Other grp (~..... _ _ _ --') : _ _ _pts 
OR 
# in single UDCA grp: , # in tnult UDCA grp: ___ _ 
Dosage of UDCA: mglkg!day 
Single or molt idose: _········-·--
Randomization complete: ____ (yes/no) 
Blinding: ___ .. __ (none), _ _ ___ (single), ___ (double), ___ (triple) 
Follow up: ___ Month lnt~rvab, _Total follow up io yrs, Duration ofTriaJ: _ _ (yrs) 
Inclusion Cr-iteria Listed:--· (yes/no), I:<::tclu ion Criteria Listed: __ (yes/no) 
Are :dl pt~ accounted for at the end or the erial: _ _ (yes/no) 
Intention to tx analysis on all pts: _ __ (yes/no) 
Primary Outcomes listed a priori: __ (yes/no) 
Ba§eliqe Chara£terjstics 
lJDCA Placebo i Other 
L --··-··· --··- ) 
Age 
Male: .Female rauo 
k # IBD pto; --------+--- - --·---·--·--· ---·-------- -----ir----------
. Bilirubin level (mg!d..!)_-+----------
AST (Ut1,) 
... A.LP-(U/L)-····--· ........ _. .... -·-····-··-·-····~··· ········--··········-···-·············--... 
r:~-'-'"--"''!--:~----+--------········-········---· ·- ···-·-·---··-··-· .. ·-·····-·······-··---···-- ·1--------~~~b~u_mm_·~(g~i/ill~) -------~---------------+---------------­
Varices (%) 
• Histology: __ 
~ ERCP: -···-···-
• tivcr Serum Tc~b: 
- Dc:ath: 
- Time to Transplant: __ 
Other {!ipccify): 
Rt>sulls of Uver Bio~:hcmi~rril:s :.~1 Onwt •>f Sttuh anJ at the En•l of Stutl\ 
End Results of Liver Histologv :1~ compared to the b~ginning of the studv 
lmprovementi ~o change \\'orscni.!!_g_ 
UDCA I Pl:lcebo VDCA I Placebo 
I I 
End Results of ERCI' as compared to the bcginnin!! of the studv 
Improvement I No change 
..... 
Wor~enine. •.. 
~.C:::A 
'1' Phtcebo (JDCA I Placebo I 
Toler aQilitv of tJDCA: (Table indic::IICS #of pts) 
·---···-·-·U...:;..;D::..C.:::.';.:A~--·----'-·-----=-P...:.I :::..:Ic:.::·ec.:::b~o-
Sille Effects Reported ! 
si'E RC(JUit"i ug Dis~;mtinuatio~-,--.. - .... _ ---------+· .... -------....... _____ _ 
ofUI>CA l 
Deaths Reported During T he Trinl : Pts Requiring Transplant During The Trial: 
r--uDe.~ _____ j__ l'lncebo__j 
[~==-----L ..... ----' 
Applicable Trial for this Mcta-Anllysis: ___ (yes/no) 
Quality Score: 
Comments: 
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Statistical Formulae 
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Statistical Formulae : 
Standard 2X2 table 
IL 
Odds Ratio (OR) : 
OR= (ad)/(bc) 
95% Confidence interval (CI) for OR: 
x2 = [n(ad-bc)2]/[(a+c)(b+d)(a+b)(c+d)] 
Test of Heterogeneity: 
sh = I:(ln(OR))2 /VI- [(I:ln(OR)/ v1)2 /(I:1/ VI)] 
v1 = (s.e.(ln(OR)) 2 
s.e.(ln(OR)) = "[(1/ai)+(1/bi)+(1/ci)+(1/di)] 
where Sh has a chi-square distribution with k-1 degrees of freedom 
k=number of trials 
Mantel- Hanenszel Estimator of the Pooled Odds Ratio 
ORmh = I:(weightiX ORi)/I:weighti 
Weighti = 1/variancei 
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95% Confidence Interval for Mantel Haenszel Eguation 
95% CI = e ln(ORmh) +I- 1.96 x sqrt(var ORmh) 
var ORmh =(IF I 2 x IR2) + [IG I (2 x l:R x l:S)] + (IHI(2 x I S2) 
where: 
F = [ai x di x (ai + di)]lni2 
G = [ai x di x (bi+ci)] + (bi x ci x (ai + di))] I ni2 
H = (bi x ci x (bi+ci)) I ni2 
R = ( ai x di) I ni 
S = (bi x ci) I ni 
Calculations for Using Standardized Mean Difference in Meta Analysis 
Starting with 
Means, SD pre and post, N, in each group 
Raw difference in means 
MeanChange(1) =Group 1 mean difference 
MeanChange(2) = Group 2 mean difference 
RawDiff = MeanChange(1)- MeanChange(2) 
SDChange(1) = Sqr(SDPre(1) " 2 + SDPost(1) " 2 - 2 * CorrPrePost * SDPre(1) * 
SDPost(1)) 
SDChange(2) = Sqr(SDPre(2) " 2 + SDPost(2) " 2 - 2 * CorrPrePost * SDPre(2) * 
SDPost(2)) 
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SDChangePooled = Sqr((((n(1) - 1) * SDChange(1) " 2 + (n(2) - 1) * SDChange(2) " 
2) I (n(1) + n(2) - 2))) 
MeanChangeDiffSE = Sqr(1 I n(1) + 1 I n(2)) * SDChangePooled 
LogOddsRatio = PI * StdDiff I Sqr(3) 
LogOddsSE = Sqr(PI " 2 * StdDiffSE " 2 I 3) 
LogOddsVariance = LogOddsSE " 2 
Where PI= 3.14159265358979 
Odds Ratio = Exp(LogOddsRatio) 



